1
|
Ahlbrand R, Wilson A, Woller P, Sachdeva Y, Lai J, Davis N, Wiggins J, Sah R. Sex-specific threat responding and neuronal engagement in carbon dioxide associated fear and extinction: Noradrenergic involvement in female mice. Neurobiol Stress 2024; 30:100617. [PMID: 38433995 PMCID: PMC10907837 DOI: 10.1016/j.ynstr.2024.100617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 02/12/2024] [Accepted: 02/13/2024] [Indexed: 03/05/2024] Open
Abstract
Difficulty in appropriately responding to threats is a key feature of psychiatric disorders, especially fear-related conditions such as panic disorder (PD) and posttraumatic stress disorder (PTSD). Most prior work on threat and fear regulation involves exposure to external threatful cues. However, fear can also be triggered by aversive, within-the-body, sensations. This interoceptive signaling of fear is highly relevant to PD and PTSD but is not well understood, especially in the context of sex. Using female and male mice, the current study investigated fear-associated spontaneous and conditioned behaviors to carbon dioxide (CO2) inhalation, a potent interoceptive threat that induces fear and panic. We also investigated whether behavioral sensitivity to CO2 is associated with delayed PTSD-relevant behaviors. CO2 evoked heterogenous freezing behaviors in both male and female animals. However, active, rearing behavior was significantly reduced in CO2-exposed male but not female mice. Interestingly, behavioral sensitivity to CO2 was associated with compromised fear extinction, independent of sex. However, in comparison to CO2-exposed males, females elicited less freezing and higher rearing during extinction suggesting an engagement of active versus passive defensive coping. Persistent neuronal activation marker ΔFosB immuno-mapping revealed attenuated engagement of infralimbic-prefrontal areas in both sexes but higher activation of brain stem locus coeruleus (LC) area in females. Inter-regional co-activation mapping revealed sex-independent disruptions in the infralimbic-amygdala associations but altered LC associations only in CO2-exposed female mice. Lastly, dopamine β hydroxylase positive (DβH + ve) noradrenergic neuronal cell counts in the LC correlated with freezing and rearing behaviors during CO2 inhalation and extinction only in female but not male mice. Collectively, these data provide evidence for higher active defensive responding to interoceptive threat CO2-associated fear in females that may stem from increased recruitment of the brainstem noradrenergic system. Our findings reveal distinct contributory mechanisms that may promote sex differences in fear and panic associated pathologies.
Collapse
Affiliation(s)
- Rebecca Ahlbrand
- Department of Pharmacology and Systems Physiology, University of Cincinnati, USA
- Veterans Affairs Medical Center, Cincinnati, OH, USA
| | - Allison Wilson
- Neuroscience Undergraduate Program, University of Cincinnati, USA
| | - Patrick Woller
- Neuroscience Graduate Program, University of Cincinnati, USA
| | - Yuv Sachdeva
- Department of Pharmacology and Systems Physiology, University of Cincinnati, USA
| | - Jayden Lai
- Department of Pharmacology and Systems Physiology, University of Cincinnati, USA
| | - Nikki Davis
- Neuroscience Undergraduate Program, University of Cincinnati, USA
| | - James Wiggins
- Neuroscience Undergraduate Program, University of Cincinnati, USA
| | - Renu Sah
- Department of Pharmacology and Systems Physiology, University of Cincinnati, USA
- Neuroscience Graduate Program, University of Cincinnati, USA
- Veterans Affairs Medical Center, Cincinnati, OH, USA
| |
Collapse
|
2
|
Fattah M, Boughton CK, Ware J, Allen JM, Hartnell S, Willinska ME, Thankamony A, de Beaufort C, Campbell FM, Fröhlich-Reiterer E, Hofer SE, Kapellen TM, Rami-Merhar B, Ghatak A, Randell TL, Besser REJ, Elleri D, Trevelyan N, Denvir Md L, Davis N, Bally L, Thabit H, Leelarathna L, Evans ML, Mader JK, Hovorka R. Evaluating the Impact of Applying Personal Glucose Targets in a Closed-Loop System for People With Type 1 Diabetes. J Diabetes Sci Technol 2024; 18:695-700. [PMID: 36540007 DOI: 10.1177/19322968221145184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND CamAPS FX is a hybrid closed-loop smartphone app used to manage type one diabetes. The closed-loop algorithm has a default target glucose of 5.8 mmol/L (104.5 mg/dL), but users can select personal glucose targets (adjustable between 4.4 mmol/L and 11.0 mmol/L [79 mg/dL and 198 mg/dL, respectively]). METHOD In this post-hoc analysis, we evaluated the impact of personal glucose targets on glycemic control using data from participants in five randomized controlled trials. RESULTS Personal glucose targets were widely used, with 20.3% of all days in the data set having a target outside the default target bin (5.5-6.0 mmol/L [99-108 mg/dL]). Personal glucose targets >6.5 mmol/L (117 mg/dL) were associated with significantly less time in target range (3.9-10.0 mmol/L [70-180 mg/dL]; 6.5-7.0 mmol/L [117-126 mg/dL]: mean difference = -3.2 percentage points [95% CI: -5.3 to -1.2; P < .001]; 7.0-7.5 mmol/L [126-135 mg/dL]: -10.8 percentage points [95% CI: -14.1 to -7.6; P < .001]). Personal targets >6.5 mmol/L (117 mg/dL) were associated with significantly lower time (<3.9 mmol/L [<70 mg/dL]; 6.5-7.0 mmol/L [117-126 mg/dL]: -1.85 percentage points [95% CI: -2.37 to -1.34; P < .001]; 7.0-7.5 mmol/L [126-135 mg/dL]: -2.68 percentage points [95% CI: -3.49 to -1.86; P < .001]). CONCLUSIONS Discrete study populations showed differences in glucose control when applying similar personal targets.
Collapse
Affiliation(s)
- Mustafa Fattah
- Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
| | - Charlotte K Boughton
- Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
- Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
- University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK
| | - Julia Ware
- Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
- Department of Paediatrics, University of Cambridge, Cambridge, UK
| | - Janet M Allen
- Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
| | - Sara Hartnell
- Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Malgorzata E Willinska
- Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
- Department of Paediatrics, University of Cambridge, Cambridge, UK
| | - Ajay Thankamony
- Department of Paediatrics, University of Cambridge, Cambridge, UK
| | - Carine de Beaufort
- Diabetes & Endocrine Care Clinique Pediatrique, Pediatric Clinic/Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg
- Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-Belval, Luxembourg
| | - Fiona M Campbell
- Department of Paediatric Diabetes, Leeds Children's Hospital, Leeds, UK
| | | | - Sabine E Hofer
- Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria
| | - Thomas M Kapellen
- Hospital for Children and Adolescents, University of Leipzig, Leipzig, Germany
| | - Birgit Rami-Merhar
- Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
| | - Atrayee Ghatak
- Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | | | - Rachel E J Besser
- Department of Paediatrics, University of Oxford, Oxford, UK
- NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK
| | - Daniela Elleri
- Royal Hospital for Children & Young People, Edinburgh, UK
| | | | | | - Nikki Davis
- Southampton Children's Hospital, Southampton, UK
| | - Lia Bally
- Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
| | - Hood Thabit
- Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester, UK
- Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| | - Lalantha Leelarathna
- Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester, UK
- Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| | - Mark L Evans
- Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
- Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Julia K Mader
- Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
| | - Roman Hovorka
- Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
- University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK
| |
Collapse
|
3
|
Milley K, Druce P, McNamara M, Bergin RJ, Chan RJ, Cust AE, Davis N, Fishman G, Jefford M, Rankin N, Yates P, Emery J. Cancer in general practice research priorities in Australia. Aust J Gen Pract 2024; 53:227-234. [PMID: 38575544 DOI: 10.31128/ajgp-02-23-6699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/06/2024]
Abstract
BACKGROUND AND OBJECTIVES The Primary Care Collaborative Cancer Clinical Trials Group (PC4) is funded by Cancer Australia to support the development of new cancer in primary care research. We undertook a research prioritisation exercise to identify cancer research priorities in Australian general practice. METHOD We adapted the nominal group technique, including a literature search and stakeholder survey. An expert group from the Primary Care Collaborative Cancer Clinical Trials Group consolidated and ranked priorities. A second stakeholder survey reviewing the top 50 priorities informed a final prioritisation workshop. RESULTS Overall, 311 priorities were identified across the cancer continuum. Nearly one-third of priorities were related to cancer survivorship and included strategies to detect recurrence, behavioural interventions and tools to assess physical and psychosocial aspects of survivorship. Prevention/early detection comprised 43.4% of priorities. Palliative care produced the least priorities (9.6%). Cross cutting research priorities (15.1%) included quality and models of care. DISCUSSION This is the first study to identify cancer research priorities for general practice in Australia. It could be used to inform the development of targeted research and funding to improve the care and outcomes for Australians affected by cancer.
Collapse
Affiliation(s)
- Kristi Milley
- BAppSci, PhD, National Manager, Primary Care Collaborative Cancer Clinical Trials Group (PC4), Department of General Practice, and Centre for Cancer Research, University of Melbourne, Vic
| | - Paige Druce
- BSc (Hons), MSc (Epi), Clinical Trial Network Coordinator, Monash University, Melbourne, Vic
| | - Mairead McNamara
- BAppSc, MDietPrac, Project Manager, Peter MacCallum Cancer Centre, Melbourne, Vic
| | - Rebecca J Bergin
- BA@Sc (Hons), PhD, Research Fellow, Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Vic; Department of General Practice/Centre for Cancer Research, University of Melbourne, Melbourne, Vic
| | - Raymond J Chan
- RN, BNurs, MAppSci, PhD, FACN, Director and Professor in Cancer Nursing, Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, SA
| | - Anne E Cust
- MPH (Hons), PhD, Head of Cancer Epidemiology and Prevention Research Group, Sydney School of Public Health and Melanoma Institute Australia, University of Sydney, NSW; Professor of Cancer Epidemiology, Sydney Medical School, University of Sydney, NSW
| | - Nikki Davis
- PC4 Community Advisory Group, Primary Care Collaborative Cancer Clinical Trials Group, Melbourne, Vic
| | - George Fishman
- PC4 Community Advisory Group, Primary Care Collaborative Cancer Clinical Trials Group, Melbourne, Vic
| | - Michael Jefford
- MBBS, MPH, MHlthServMt, PhD, FRACP, Consultant Medical Oncologist, Department of Medical Oncology, Peter MacCallum Cancer Centre, Vic; Director, Australian Cancer Survivorship Centre, A Richard Pratt Legacy, Peter MacCallum Cancer Centre, Vic; Lead, Survivorship and Living Well After Cancer Research, Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, Vic; Professor, Sir Peter MacCallum Department of Oncology, University of Melbourne
| | - Nicole Rankin
- PhD, Head, Evaluation and Implementation Science Unit, The University of Sydney, Sydney, NSW
| | - Patsy Yates
- AM, PhD, RN, FACN, FAAN, Executive Dean of the Faculty of Health, Centre for Health Policy, The University of Melbourne, Melbourne, Vic
| | - Jon Emery
- MA, MBBCh, FRACGP, MRCGP, DPhil, Herman Professor of Primary Care Cancer Research, Department of General Practice and Centre for Cancer Research, University of Melbourne, Melbourne, Vic
| |
Collapse
|
4
|
Fox DS, Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, Thankamony A, Campbell F, Wadwa RP, Buckingham BA, Davis N, DiMeglio LA, Mauras N, Besser REJ, Ghatak A, Weinzimer SA, Kanapka L, Kollman C, Sibayan J, Beck RW, Hood KK, Hovorka R. Cost-Effectiveness of Closed-Loop Automated Insulin Delivery Using the Cambridge Hybrid Algorithm in Children and Adolescents with Type 1 Diabetes: Results from a Multicenter 6-Month Randomized Trial. J Diabetes Sci Technol 2024:19322968241231950. [PMID: 38494876 DOI: 10.1177/19322968241231950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/19/2024]
Abstract
BACKGROUND/OBJECTIVE The main objective of this study is to evaluate the incremental cost-effectiveness (ICER) of the Cambridge hybrid closed-loop automated insulin delivery (AID) algorithm versus usual care for children and adolescents with type 1 diabetes (T1D). METHODS This multicenter, binational, parallel-controlled trial randomized 133 insulin pump using participants aged 6 to 18 years to either AID (n = 65) or usual care (n = 68) for 6 months. Both within-trial and lifetime cost-effectiveness were analyzed. Analysis focused on the treatment subgroup (n = 21) who received the much more reliable CamAPS FX hardware iteration and their contemporaneous control group (n = 24). Lifetime complications and costs were simulated via an updated Sheffield T1D policy model. RESULTS Within-trial, both groups had indistinguishable and statistically unchanged health-related quality of life, and statistically similar hypoglycemia, severe hypoglycemia, and diabetic ketoacidosis (DKA) event rates. Total health care utilization was higher in the treatment group. Both the overall treatment group and CamAPS FX subgroup exhibited improved HbA1C (-0.32%, 95% CI: -0.59 to -0.04; P = .02, and -1.05%, 95% CI: -1.43 to -0.67; P < .001, respectively). Modeling projected increased expected lifespan of 5.36 years and discounted quality-adjusted life years (QALYs) of 1.16 (U.K. tariffs) and 1.52 (U.S. tariffs) in the CamAPS FX subgroup. Estimated ICERs for the subgroup were £19 324/QALY (United Kingdom) and -$3917/QALY (United States). For subgroup patients already using continuous glucose monitors (CGM), ICERs were £10 096/QALY (United Kingdom) and -$33 616/QALY (United States). Probabilistic sensitivity analysis generated mean ICERs of £19 342/QALY (95% CI: £15 903/QALY to £22 929/QALY) (United Kingdom) and -$28 283/QALY (95% CI: -$59 607/QALY to $1858/QALY) (United States). CONCLUSIONS For children and adolescents with T1D on insulin pump therapy, AID using the Cambridge algorithm appears cost-effective below a £20 000/QALY threshold (United Kingdom) and cost saving (United States).
Collapse
Affiliation(s)
- D Steven Fox
- Department of Pharmaceutical and Health Economics, Mann School of Pharmacy, University of Southern California, Los Angeles, CA, USA
| | - Julia Ware
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
- Department of Paediatrics, University of Cambridge, Cambridge, UK
| | - Charlotte K Boughton
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
- Department of Diabetes & Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Janet M Allen
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
| | - Malgorzata E Wilinska
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
- Department of Paediatrics, University of Cambridge, Cambridge, UK
| | - Martin Tauschmann
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
- Department of Paediatrics, University of Cambridge, Cambridge, UK
| | - Louise Denvir
- Department of Paediatric Diabetes and Endocrinology, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Ajay Thankamony
- Department of Paediatrics, University of Cambridge, Cambridge, UK
| | - Fiona Campbell
- Department of Paediatric Diabetes, Leeds Children's Hospital, Leeds, UK
| | - R Paul Wadwa
- Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - Bruce A Buckingham
- Stanford University School of Medicine, Stanford Diabetes Research Center, Stanford, CA, USA
| | - Nikki Davis
- Department of Paediatric Endocrinology and Diabetes, Southampton Children's Hospital, Southampton General Hospital, Southampton, UK
| | - Linda A DiMeglio
- Division of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Nelly Mauras
- Nemours Children's Health, Jacksonville, FL, USA
| | - Rachel E J Besser
- Oxford University Hospitals NHS Foundation Trust, NIHR Oxford Biomedical Research Centre, Oxford, UK
- Department of Paediatrics, University of Oxford, Oxford, UK
| | | | | | | | | | - Judy Sibayan
- The Jaeb Center for Health Research, Tampa, FL, USA
| | - Roy W Beck
- The Jaeb Center for Health Research, Tampa, FL, USA
| | - Korey K Hood
- Stanford University School of Medicine, Stanford Diabetes Research Center, Stanford, CA, USA
| | - Roman Hovorka
- Department of Pharmaceutical and Health Economics, Mann School of Pharmacy, University of Southern California, Los Angeles, CA, USA
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
| |
Collapse
|
5
|
van Boxel EJ, Rahman S, Lai K, Boulos N, Davis N. Semaglutide treatment for children with obesity: an observational study. Arch Dis Child 2024:archdischild-2023-326687. [PMID: 38471743 DOI: 10.1136/archdischild-2023-326687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Accepted: 02/25/2024] [Indexed: 03/14/2024]
Abstract
OBJECTIVE To assess efficacy and tolerability of semaglutide as a weight loss treatment for children living with comorbid obesity. DESIGN Retrospective observational study of the first 50 children from a weight management service treated with semaglutide for at least 6 months. SETTING A tertiary paediatric multidisciplinary weight management clinic in a UK hospital. PATIENTS Aged 10-18 years old with a body mass index (BMI) SD score (SDS) >2 with a weight-related comorbidity (including insulin resistance (defined as homeostatic model assessment for insulin resistance >4), type 2 diabetes, metabolic-associated fatty liver disease, obstructive sleep apnoea or hypertension). INTERVENTIONS Once-weekly injectable semaglutide titrated over 8 weeks to a final dose of 1 mg in addition to dietary and lifestyle advice. MAIN OUTCOME MEASURES Primary outcome measures were change in weight, BMI SDS and percentage body weight. Secondary outcomes were side effects and cessation of treatment. RESULTS After 6 months of treatment, statistically significant decreases in BMI SDS (0.32±0.27, p<0.001) and body weight (7.03±7.50 kg, p<0.001) were seen. Mean percentage total weight loss was 6.4±6.3% (p<0.001). For the 14 patients for whom 12-month data were available, statistically significant decreases were seen in mean BMI SDS (0.54±0.52, p<0.001). Mean body weight decreased by 9.7±10.8 kg (p<0.001). Percentage total weight loss at 12 months was 8.9±10.0% (p<0.001). Mild gastrointestinal side effects were common. One patient developed gallstones. Five patients discontinued treatment due to side effects. CONCLUSION Semaglutide appears to be a safe and effective weight loss adjunct when used in a multidisciplinary weight management clinic.
Collapse
Affiliation(s)
| | | | - Karen Lai
- Southampton General Hospital, Southampton, UK
| | | | - Nikki Davis
- Southampton General Hospital, Southampton, UK
| |
Collapse
|
6
|
Oyediran K, Davis N. Relationship between health insurance enrolment and unintended pregnancy in Ghana. J Biosoc Sci 2024; 56:104-124. [PMID: 36852702 DOI: 10.1017/s0021932023000032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
CONTEXT The effect of health insurance coverage on sexual and reproductive health, especially unintended pregnancy, has scantly been researched. Using the 2014 Ghana Demographic and Health Survey, the study examined the links between women's health insurance enrolment on unintended pregnancy in Ghana. METHOD The sample consisted of 9,396 women aged 15-49 years, but the analysis was limited to the 4,544 women who were pregnant in the two years preceding the survey. The effects of health insurance enrolment on unintended pregnancy was examined with the propensity score matching. The health insurance enrolment was the treatment variable and unintended pregnancy as the outcome variable. RESULTS This study showed that 66.0% of all women surveyed had health insurance coverage and 31.8% of all women of childbearing age who were currently or had previously been pregnant reported having at least one unintended pregnancy. Thirty percent of insured women had an unintended pregnancy, compared to 37% of uninsured women. The results showed that education, household wealth index, religion, and type of marital union were significant predictor of health insurance coverage among Ghanaian women. The PSM split the women based on their health insurance status. After matching, the difference between the insured and uninsured women reduces significantly. Results demonstrated that, the probability of unintended pregnancy was 0.312 among insured women and 0.351 among those not insured in Ghana. This implies that having health insurance coverage will help in reducing the likelihood of women experiencing unintended pregnancy. CONCLUSIONS Results highlight the importance of the target of universal health coverage under the sustainable development goal 3 and demonstrate that expanding existing health insurance schemes within Ghana could contribute to reducing the number unintended pregnancies experienced each year.
Collapse
Affiliation(s)
| | - Nikki Davis
- Senior Research, Monitoring, and Evaluation Advisor John Snow Inc.Arlington, VA22202
| |
Collapse
|
7
|
Alwan H, Ware J, Boughton CK, Wilinska M, Allen JM, Lakshman R, Nwokolo M, Hartnell S, Bally L, de Beaufort C, Besser REJ, Campbell F, Davis N, Denver L, Evants ML, Fröhlich-Reiterer E, Ghatak A, Hofer SE, Kapellen TM, Leelarathna L, Mader JK, Narendran P, Rami-Merhar B, Tauschmann M, Thabit H, Thankamony A, Hovorka R. Time spent in hypoglycemia according to age and time-of-day: Observations during closed-loop insulin delivery. Diabetes Technol Ther 2023. [PMID: 37229591 DOI: 10.1089/dia.2023.0061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
OBJECTIVE We aimed to assess whether percentage of time spent in hypoglycemia during closed-loop insulin delivery differs by age-group and time-of-day. METHODS We retrospectively analyzed data from hybrid closed-loop studies involving young children (2-7 years), children and adolescents (8-18 years), adults (19-59 years), and older adults (≥60 years) with type 1 diabetes. Main outcome was time spent in hypoglycemia <3.9mmol/l. Eight weeks of data for 88 participants were analyzed. RESULTS Median time spent in hypoglycemia over the 24-hour period was highest in children and adolescents (4.4%; [IQR 2.4-5.0]) and very young children (4.0% [3.4-5.2]), followed by adults (2.7% [1.7-4.0]), and older adults (1.8% [1.2-2.2]); p<0.001 for difference between age-groups. Time spent in hypoglycemia during nighttime (midnight-05:59) was lower than during daytime (06:00-23:59) across all age-groups. CONCLUSION Time in hypoglycemia was highest in the pediatric age-group during closed-loop insulin delivery. Hypoglycemia burden was lowest overnight across all age-groups.
Collapse
Affiliation(s)
- Heba Alwan
- University of Cambridge, 2152, Wellcome Trust- MRC Institute of Metabolic Science, Cambridge, United Kingdom of Great Britain and Northern Ireland
- University of Bern, 27210, Institute of Primary Health Care (BIHAM), Bern, Bern, Switzerland
- University of Bern, 27210, Graduate School for Health Sciences, Bern, Bern, Switzerland;
| | - Julia Ware
- University of Cambridge, 2152, Wellcome-MRC Institute of Metabolic Science, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland
- University of Cambridge, 2152, Department of Paediatrics, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland;
| | - Charlotte K Boughton
- University of Cambridge, 2152, Wellcome-MRC Institute of Metabolic Science, Cambridge, United Kingdom of Great Britain and Northern Ireland
- Cambridge University Hospitals NHS Foundation Trust, 2153, Department of Diabetes and Endocrinology, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland;
| | - Malgorzata Wilinska
- University of Cambridge, 2152, Wellcome-MRC Institute of Metabolic Science, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland
- University of Cambridge, 2152, Department of Paediatrics, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland;
| | - Janet M Allen
- University of Cambridge, 2152, Wellcome-MRC Institute of Metabolic Science, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland;
| | - Rama Lakshman
- University of Cambridge, 2152, Wellcome-MRC Institute of Metabolic Science, Cambridge, United Kingdom of Great Britain and Northern Ireland;
| | - Munachiso Nwokolo
- University of Cambridge, 2152, Wellcome-MRC Institute of Metabolic Science, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland;
| | - Sara Hartnell
- University of Cambridge, 2152, Wellcome-MRC Institute of Metabolic Science, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland;
| | - Lia Bally
- Bern University Hospital and University of Bern, Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Bern, Switzerland;
| | - Carine de Beaufort
- UZ-VUB, Department of Paediatric Endocrinology, Jette, Belgium
- Centre Hospitalier de Luxembourg, DECCP, Clinique Pédiatrique, Luxembourg, Luxembourg;
| | - Rachel Elizabeth Jane Besser
- Oxford University Hospitals NHS Trust, 6397, NIHR Oxford Biomedical Research Centre, Oxford, Oxfordshire, United Kingdom of Great Britain and Northern Ireland
- University of Oxford, 6396, Department of Paediatrics, Oxford, Oxfordshire, United Kingdom of Great Britain and Northern Ireland;
| | - Fiona Campbell
- Leeds Children's Hospital, Department of Paediatric Diabetes, Leeds, United Kingdom of Great Britain and Northern Ireland;
| | - Nikki Davis
- Southampton Children's Hospital, 567681, Department of Paediatric Endocrinology and Diabetes, Southampton, United Kingdom of Great Britain and Northern Ireland;
| | - Louise Denver
- Nottingham University Hospitals NHS Trust, 9820, Department of Paediatric Diabetes and Endocrinology, Nottingham, United Kingdom of Great Britain and Northern Ireland;
| | - Mark L Evants
- University of Cambridge, 2152, Wellcome-MRC Institute of Metabolic Science, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland
- Cambridge University Hospitals NHS Foundation Trust, 2153, Department of Diabetes and Endocrinology, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland;
| | - Elke Fröhlich-Reiterer
- Medical University of Graz, 31475, Department of Pediatrics and Adolescent Medicine, Graz, Steiermark, Austria;
| | - Atrayee Ghatak
- Alder Hey Children's NHS Foundation Trust, 4593, Department of Paediatrics, Liverpool, Liverpool, United Kingdom of Great Britain and Northern Ireland;
| | - Sabine E Hofer
- Medical University of Innsbruck, 27280, Department of Pediatrics, Innsbruck, Tirol, Austria;
| | - Thomas M Kapellen
- University of Leipzig, Hospital for Children and Adolescents, Leipzig, Germany
- Median Kinderklinik am Nicolausholz, Naumburg, Germany;
| | - Lalantha Leelarathna
- Manchester University NHS Foundation Trust, 5293, Diabetes, Endocrinology and Metabolism Centre, Manchester, Greater Manchester, United Kingdom of Great Britain and Northern Ireland
- University of Manchester, Division of Diabetes, Endocrinology and Gastroenterology, Manchester, United Kingdom of Great Britain and Northern Ireland;
| | - Julia K Mader
- Medical University of Graz, 31475, , Division of Endocrinology and Diabetology, Graz, Steiermark, Austria;
| | - Parth Narendran
- Queen Elizabeth Hospital, 156807, Department of Endocrinology and Diabetes, Birmingham, United Kingdom , Birmingham, United Kingdom of Great Britain and Northern Ireland
- University of Birmingham, 1724, Institute of Immunology and Immunotherapy, Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland;
| | - Birgit Rami-Merhar
- Medical University of Vienna, 27271, Department of Paediatrics and Adolescent Medicine, Wien, Wien, Austria;
| | - Martin Tauschmann
- Medical University of Vienna, 27271, Department of Pediatrics and Adolescent Medicine, Wien, Wien, Austria;
| | - Hood Thabit
- Manchester University NHS Foundation Trust, 5293, Diabetes, Endocrinology and Metabolism Centre, Manchester, Greater Manchester, United Kingdom of Great Britain and Northern Ireland
- Manchester Academic Health Science Centre, 158986, Diabetes, Endocrinology and Metabolism Centre, Manchester, Manchester, United Kingdom of Great Britain and Northern Ireland;
| | - Ajay Thankamony
- University of Cambridge, 2152, Department of Paediatrics, Cambridge, United Kingdom of Great Britain and Northern Ireland;
| | - Roman Hovorka
- University of Cambridge, 2152, Wellcome-MRC Institute of Metabolic Science, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland
- University of Cambridge, 2152, Department of Paediatrics, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland;
| |
Collapse
|
8
|
Bergin RJ, Short CE, Davis N, Marker J, Dawson MT, Milton S, McNamara M, Druce P, Milley K, Karnchanachari N, Skaczkowski G. The nature and impact of patient and public involvement in cancer prevention, screening and early detection research: A systematic review. Prev Med 2023; 167:107412. [PMID: 36592674 DOI: 10.1016/j.ypmed.2022.107412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Revised: 11/23/2022] [Accepted: 12/28/2022] [Indexed: 12/31/2022]
Abstract
Patient and public involvement can produce high-quality, relevant research that better addresses the needs of patients and their families. This systematic review investigated the nature and impact of patient and public involvement in cancer prevention, screening and early detection research. Two patient representatives were involved as members of the review team. Databases (Medline, EMBASE, Emcare, Involve Evidence Library) were searched for English-language studies published 1995-March 2022. Titles/abstracts were screened by two reviewers independently. For eligible studies, data were extracted on study characteristics, patient and public involvement (who, when, how, and impact on research outcomes), and reporting quality using the Guidance for Reporting Involvement of Patients and the Public 2-Short Form. Of 4095 articles screened, 58 were eligible. Most research was from the United States (81%) and examined cancer screening or prevention (82%). Community members/organisations/public were the most involved (71%); fewer studies involved patients and/or carers (14%). Over half reported a high-level of involvement (i.e. partner and/or expert involvement), although this declined in later stages of the research cycle, e.g. data analysis. Common positive impacts included improved study design, research methods and recruitment, although most papers (62%) did not describe methods to determine impact. Reporting quality was sub-optimal, largely due to failure to consider challenges. This review found that high-level involvement of patients and the public in cancer prevention, screening and early detection research is feasible and has several advantages. However, improvements are needed to encourage involvement across the research cycle, and in evaluating and reporting its impact.
Collapse
Affiliation(s)
- Rebecca J Bergin
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia; Department of General Practice/Centre for Cancer Research, University of Melbourne, Melbourne, Australia.
| | - Camille E Short
- Melbourne Centre for Behaviour Change, Melbourne School of Psychological Sciences and Melbourne School of Health Sciences, University of Melbourne, Melbourne, Australia
| | - Nikki Davis
- Patient representative, Primary Care Collaborative Cancer Clinical Trials Group (PC4) Community Advisory Group, Melbourne, Australia
| | - Julie Marker
- Patient representative, Primary Care Collaborative Cancer Clinical Trials Group (PC4) Community Advisory Group, Melbourne, Australia; Patient representative, Cancer Voices South Australia, Adelaide, Australia
| | | | - Shakira Milton
- Department of General Practice/Centre for Cancer Research, University of Melbourne, Melbourne, Australia
| | - Mairead McNamara
- Department of General Practice/Centre for Cancer Research, University of Melbourne, Melbourne, Australia
| | - Paige Druce
- Department of General Practice/Centre for Cancer Research, University of Melbourne, Melbourne, Australia; Central Clinical School, Monash University, Melbourne, Australia
| | - Kristi Milley
- Department of General Practice/Centre for Cancer Research, University of Melbourne, Melbourne, Australia
| | - Napin Karnchanachari
- Department of General Practice/Centre for Cancer Research, University of Melbourne, Melbourne, Australia
| | - Gemma Skaczkowski
- Department of Rural Health, Allied Health and Human Performance, University of South Australia, Adelaide, Australia; School of Psychology & Public Health, La Trobe University, Melbourne, Australia
| |
Collapse
|
9
|
Hood KK, Garcia‐Willingham N, Hanes S, Tanenbaum ML, Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, Thankamony A, Campbell F, Wadwa RP, Buckingham BA, Davis N, DiMeglio LA, Mauras N, Besser REJ, Ghatak A, Weinzimer SA, Fox DS, Kanapka L, Kollman C, Sibayan J, Beck RW, Hovorka R. Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents. Diabetes Obes Metab 2022; 24:2309-2318. [PMID: 35837984 PMCID: PMC9804666 DOI: 10.1111/dom.14815] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Revised: 07/06/2022] [Accepted: 07/11/2022] [Indexed: 01/09/2023]
Abstract
AIM To examine changes in the lived experience of type 1 diabetes after use of hybrid closed loop (CL), including the CamAPS FX CL system. MATERIALS AND METHODS The primary study was conducted as an open-label, single-period, randomized, parallel design contrasting CL versus insulin pump (with or without continuous glucose monitoring). Participants were asked to complete patient-reported outcomes before starting CL and 3 and 6 months later. Surveys assessed diabetes distress, hypoglycaemia concerns and quality of life. Qualitative focus group data were collected at the completion of the study. RESULTS In this sample of 98 youth (age range 6-18, mean age 12.7 ± 2.8 years) and their parents, CL use was not associated with psychosocial benefits overall. However, the subgroup (n = 12) using the CamAPS FX system showed modest improvements in quality of life and parent distress, reinforced by both survey (p < .05) and focus group responses. There were no negative effects of CL use reported by study participants. CONCLUSIONS Closed loop use via the CamAPS FX system was associated with modest improvements in aspects of the lived experience of managing type 1 diabetes in youth and their families. Further refinements of the system may optimize the user experience.
Collapse
Affiliation(s)
- Korey K. Hood
- Stanford University School of MedicineStanford Diabetes Research CenterStanfordCaliforniaUSA
| | | | - Sarah Hanes
- Stanford University School of MedicineStanford Diabetes Research CenterStanfordCaliforniaUSA
| | - Molly L. Tanenbaum
- Stanford University School of MedicineStanford Diabetes Research CenterStanfordCaliforniaUSA
| | - Julia Ware
- Wellcome Trust‐MRC Institute of Metabolic ScienceUniversity of CambridgeCambridgeUK
- Department of PaediatricsUniversity of CambridgeCambridgeUK
| | - Charlotte K. Boughton
- Wellcome Trust‐MRC Institute of Metabolic ScienceUniversity of CambridgeCambridgeUK
- Department of Diabetes & EndocrinologyCambridge University Hospitals NHS Foundation TrustCambridgeUK
| | - Janet M. Allen
- Wellcome Trust‐MRC Institute of Metabolic ScienceUniversity of CambridgeCambridgeUK
| | - Malgorzata E. Wilinska
- Wellcome Trust‐MRC Institute of Metabolic ScienceUniversity of CambridgeCambridgeUK
- Department of PaediatricsUniversity of CambridgeCambridgeUK
| | - Martin Tauschmann
- Wellcome Trust‐MRC Institute of Metabolic ScienceUniversity of CambridgeCambridgeUK
- Department of PaediatricsUniversity of CambridgeCambridgeUK
| | - Louise Denvir
- Department of Paediatric Diabetes and EndocrinologyNottingham University Hospitals NHS TrustNottinghamUK
| | | | - Fiona Campbell
- Department of Paediatric DiabetesLeeds Children's HospitalLeedsUK
| | - R. Paul Wadwa
- Barbara Davis Center for Childhood DiabetesUniversity of Colorado Anschutz Medical CampusAuroraColoradoUSA
| | - Bruce A. Buckingham
- Stanford University School of MedicineStanford Diabetes Research CenterStanfordCaliforniaUSA
| | - Nikki Davis
- Department of Paediatric Endocrinology and Diabetes, Southampton Children's HospitalSouthampton General HospitalSouthamptonUK
| | - Linda A. DiMeglio
- Department of Pediatrics, Division of Pediatric Endocrinology and Diabetology, Wells Center for Pediatric ResearchIndiana University School of MedicineIndianapolisIndianaUSA
| | - Nelly Mauras
- Division of Endocrinology, Diabetes & MetabolismNemours Children's HealthJacksonvilleFloridaUSA
| | - Rachel E. J. Besser
- Oxford University Hospitals NHS Foundation TrustNIHR Oxford Biomedical Research CentreOxfordUK
- University of OxfordDepartment of PaediatricsOxfordUK
| | | | | | - D. Steven Fox
- Department of Pharmaceutical and Health Economics, School of PharmacyUniversity of Southern CaliforniaLos AngelesCaliforniaUSA
| | | | | | - Judy Sibayan
- The Jaeb Center for Health ResearchTampaFloridaUSA
| | - Roy W. Beck
- The Jaeb Center for Health ResearchTampaFloridaUSA
| | - Roman Hovorka
- Wellcome Trust‐MRC Institute of Metabolic ScienceUniversity of CambridgeCambridgeUK
| | | |
Collapse
|
10
|
Smith R, Campbell A, Montgomery S, Best L, Foad F, Davis N, O'Boyle S, Thirlby-Moore S, Macpherson S, Davies L, Barrie A. Is the time of appearance of vacuoles critical to live birth outcome? Reprod Biomed Online 2022. [DOI: 10.1016/j.rbmo.2022.08.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
11
|
Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, Thankamony A, Campbell FM, Wadwa RP, Buckingham BA, Davis N, DiMeglio LA, Mauras N, Besser REJ, Ghatak A, Weinzimer SA, Hood KK, Fox DS, Kanapka L, Kollman C, Sibayan J, Beck RW, Hovorka R. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. Lancet Digit Health 2022; 4:e245-e255. [PMID: 35272971 DOI: 10.1016/s2589-7500(22)00020-6] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Revised: 12/10/2021] [Accepted: 01/25/2022] [Indexed: 02/07/2023]
Abstract
BACKGROUND Closed-loop insulin delivery systems have the potential to address suboptimal glucose control in children and adolescents with type 1 diabetes. We compared safety and efficacy of the Cambridge hybrid closed-loop algorithm with usual care over 6 months in this population. METHODS In a multicentre, multinational, parallel randomised controlled trial, participants aged 6-18 years using insulin pump therapy were recruited at seven UK and five US paediatric diabetes centres. Key inclusion criteria were diagnosis of type 1 diabetes for at least 12 months, insulin pump therapy for at least 3 months, and screening HbA1c levels between 53 and 86 mmol/mol (7·0-10·0%). Using block randomisation and central randomisation software, we randomly assigned participants to either closed-loop insulin delivery (closed-loop group) or to usual care with insulin pump therapy (control group) for 6 months. Randomisation was stratified at each centre by local baseline HbA1c. The Cambridge closed-loop algorithm running on a smartphone was used with either (1) a modified Medtronic 640G pump, Medtronic Guardian 3 sensor, and Medtronic prototype phone enclosure (FlorenceM configuration), or (2) a Sooil Dana RS pump and Dexcom G6 sensor (CamAPS FX configuration). The primary endpoint was change in HbA1c at 6 months combining data from both configurations. The primary analysis was done in all randomised patients (intention to treat). Trial registration ClinicalTrials.gov, NCT02925299. FINDINGS Of 147 people initially screened, 133 participants (mean age 13·0 years [SD 2·8]; 57% female, 43% male) were randomly assigned to either the closed-loop group (n=65) or the control group (n=68). Mean baseline HbA1c was 8·2% (SD 0·7) in the closed-loop group and 8·3% (0·7) in the control group. At 6 months, HbA1c was lower in the closed-loop group than in the control group (between-group difference -3·5 mmol/mol (95% CI -6·5 to -0·5 [-0·32 percentage points, -0·59 to -0·04]; p=0·023). Closed-loop usage was low with FlorenceM due to failing phone enclosures (median 40% [IQR 26-53]), but consistently high with CamAPS FX (93% [88-96]), impacting efficacy. A total of 155 adverse events occurred after randomisation (67 in the closed-loop group, 88 in the control group), including seven severe hypoglycaemia events (four in the closed-loop group, three in the control group), two diabetic ketoacidosis events (both in the closed-loop group), and two non-treatment-related serious adverse events. There were 23 reportable hyperglycaemia events (11 in the closed-loop group, 12 in the control group), which did not meet criteria for diabetic ketoacidosis. INTERPRETATION The Cambridge hybrid closed-loop algorithm had an acceptable safety profile, and improved glycaemic control in children and adolescents with type 1 diabetes. To ensure optimal efficacy of the closed-loop system, usage needs to be consistently high, as demonstrated with CamAPS FX. FUNDING National Institute of Diabetes and Digestive and Kidney Diseases.
Collapse
Affiliation(s)
- Julia Ware
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Department of Paediatrics, University of Cambridge, Cambridge, UK
| | - Charlotte K Boughton
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Department of Diabetes & Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Janet M Allen
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
| | - Malgorzata E Wilinska
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Department of Paediatrics, University of Cambridge, Cambridge, UK
| | - Martin Tauschmann
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Department of Paediatrics, University of Cambridge, Cambridge, UK
| | - Louise Denvir
- Department of Paediatric Diabetes and Endocrinology, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Ajay Thankamony
- Department of Paediatrics, University of Cambridge, Cambridge, UK
| | - Fiona M Campbell
- Department of Paediatric Diabetes, Leeds Children's Hospital, Leeds, UK
| | - R Paul Wadwa
- Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - Bruce A Buckingham
- Division of Pediatric Endocrinology, Stanford University, Stanford, CA, USA
| | - Nikki Davis
- Department of Paediatric Endocrinology and Diabetes, Southampton Children's Hospital, Southampton General Hospital, Southampton, UK
| | - Linda A DiMeglio
- Department of Pediatrics, Division of Pediatric Endocrinology and Diabetology, Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Nelly Mauras
- Division of Endocrinology, Diabetes & Metabolism, Nemours Children's Health System, Jacksonville, FL, USA
| | - Rachel E J Besser
- Oxford University Hospitals NHS Foundation Trust, NIHR Oxford Biomedical Research Centre, Oxford, UK; Department of Paediatrics, University of Oxford, Oxford, UK
| | | | | | - Korey K Hood
- Division of Pediatric Endocrinology, Stanford University, Stanford, CA, USA
| | - D Steven Fox
- Department of Pharmaceutical and Health Economics, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
| | | | | | - Judy Sibayan
- The Jaeb Center for Health Research, Tampa, FL, USA
| | - Roy W Beck
- The Jaeb Center for Health Research, Tampa, FL, USA
| | - Roman Hovorka
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Department of Paediatrics, University of Cambridge, Cambridge, UK.
| |
Collapse
|
12
|
Logan A, Davis N, Delk I, Hassett L, Olson S, Patel K. Characterization of Lung Transplant COVID19+ Patients and Mortality Outcomes. J Heart Lung Transplant 2022. [PMCID: PMC8988559 DOI: 10.1016/j.healun.2022.01.1549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Purpose The aim of this study is to report the characteristic and mortality outcomes of lung transplant patients that contracted COVID19. Methods A retrospective chart review was conducted of lung transplant recipients who tested positive for COVID19 from 6/1/2020 to 9/1/2021. Results Forty-five patients were included for mortality incidence review with 2 patients who were admitted to outside facilities during their COVID diagnosis with limited treatment data. Mortality incidence was 15.5% with cohort mean age of 62 (±11.7). Median time from transplant to infection was 1281 days (223-5800). Five patients required O2 and n=5 were intubated with 80% mortality (n=4) among those intubated. Baseline demographics of age, gender, indication for transplant or race were not statistically different among patients that died vs those that survived. Vaccinations (2 doses) prior to infection were evident in n=35 (77.8%) of the patients. Maintenance immunosuppressants and covid therapies (table 1) did not have an associated difference in survival from infection. A significant association with mortality was found from the time of reported symptoms to triage or hospitalization in those that survived vs died, 3.3 vs 9.4 days (p=0.003). Conclusion This is one of the largest cohorts reporting lung transplant recipients who contracted COVID19, and despite lungs being the organ directly affected by COVID19, mortality rates are comparable to rates reported in other solid organ transplants. Time to triage from symptom onset to clinic management or hospital admission for COVID appears to be associated with improved mortality rates.
Collapse
|
13
|
Shankar S, Logan A, Davis N, Baker L, Patel K. Outcomes in Single versus Standard Dose Basiliximab After Lung Transplant. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
14
|
Harmer MJ, Everitt LH, Parker L, Davis N, Connett G, Nagra A. Structured transition is associated with improved outcomes in diabetes. Practical Diabetes 2022. [DOI: 10.1002/pdi.2375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Matthew J Harmer
- Southampton Children's Hospital University Hospital Southampton NHS Foundation Trust Southampton UK
- University of Southampton Southampton UK
- NIHR Southampton Biomedical Research Centre – Nutrition University Hospital Southampton NHS Foundation Trust Southampton General Hospital UK
| | - Lucy H Everitt
- Southampton Children's Hospital University Hospital Southampton NHS Foundation Trust Southampton UK
- Health Education England Wessex School of Quality Improvement UK
| | - Lillie Parker
- Southampton Children's Hospital University Hospital Southampton NHS Foundation Trust Southampton UK
- University of Southampton Southampton UK
| | - Nikki Davis
- Southampton Children's Hospital University Hospital Southampton NHS Foundation Trust Southampton UK
| | - Gary Connett
- Southampton Children's Hospital University Hospital Southampton NHS Foundation Trust Southampton UK
| | - Arvind Nagra
- Southampton Children's Hospital University Hospital Southampton NHS Foundation Trust Southampton UK
| |
Collapse
|
15
|
Ee C, Singleton AC, de Manincor M, Elder E, Davis N, Mitchell C, Dune T, MacMillan F, McBride K, Grant S. A Qualitative Study Exploring Feasibility and Acceptability of Acupuncture, Yoga, and Mindfulness Meditation for Managing Weight After Breast Cancer. Integr Cancer Ther 2022; 21:15347354221099540. [PMID: 35652533 PMCID: PMC9168877 DOI: 10.1177/15347354221099540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Introduction: Weight gain is common after breast cancer. Yoga, mindfulness meditation, and
acupuncture may assist with managing weight. However, evidence on
effectiveness is limited. This study assessed the feasibility and
acceptability of recruiting for and implementing a randomized controlled
trial (RCT) evaluating these interventions as adjuncts to lifestyle
interventions (diet and exercise) for weight management in women with breast
cancer. Methods: Qualitative study involving virtual focus groups or semi-structured
interviews. Participants were recruited via email invitation from a breast
cancer consumer organization and breast cancer center in Australia. Eligible
participants had received treatment for breast cancer, and were fluent in
English. A purposive sample of culturally and linguistically diverse (CALD)
participants was also recruited. Focus groups and interviews were
audio-recorded, transcribed verbatim and analyzed using thematic analysis
with the constant comparison method. Results: Emails were sent to 1415 women of which 37 provided data in 5 focus groups
and 1 semi-structured interview, including 1 focus group (n = 6) with only
women from CALD backgrounds. Yoga and mindfulness meditation were perceived
as feasible and acceptable for weight management, but acupuncture was seen
to be too invasive to be acceptable. A focus on wellness rather than weight
reduction, flexible program delivery, trusted advice, consideration of
participant burden and benefit, and peer-support were key factors perceived
to increase feasibility and acceptability. Conclusions: Yoga and mindfulness meditation are acceptable and useful adjuncts to
lifestyle interventions for weight management after breast cancer. This
research places end-users at the forefront of trial design, and will inform
future trials using these interventions for weight management and improving
health and wellbeing after breast cancer.
Collapse
Affiliation(s)
- Carolyn Ee
- Western Sydney University, Penrith, NSW, Australia
| | - Anna C Singleton
- Engagement and Co-Design Research Hub, Faculty of Medicine and Health, School of Health Sciences, University of Sydney, Westmead, NSW, Australia
| | | | | | - Nikki Davis
- Primary Care Collaborative Cancer Clinical Trials Group, Melbourne, VIC, Australia
| | | | - Tinashe Dune
- Western Sydney University, Penrith, NSW, Australia
| | | | - Kate McBride
- Western Sydney University, Penrith, NSW, Australia
| | | |
Collapse
|
16
|
Barrie A, Smith R, Best L, Davis N, Duffy S, Krokos S, Lodge Y, Montgomery S, O’Boyle S, Thirlby-Moore S, Whitten B, Campbell A. P–222 Can we optimise the time that we perform the fertilisation check in the lab? Lessons learnt from time-lapse incubation. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Can time-lapse data be used to identify the optimum time to perform the fertilisation check for oocytes cultured in standard incubation?
Summary answer
The optimum time to perform fertilisation checks for oocytes cultured in standard incubation is 16.5hpi+/–0.5h.
What is known already
Time-lapse incubation allows the embryologist to retrospectively review collated images of oocytes and embryos to capture important embryological observations that may have otherwise been missed. This is a luxury not available to embryologists when oocytes or embryos are cultured in standard incubation. Traditionally, the optimum time to perform the fertilisation check is 17 hours post insemination (hpi) +/- 1 hour. It was hypothesised that this could be fine-tuned ensuring the maximum number of fertilised oocytes were observed, thereby increasing the number of usable embryos for the patient.
Study design, size, duration
This was a retrospective, multicentre analysis including data from 27,022 ICSI derived embryos cultured in time-lapse incubation between January 2011 to November 2019.
Participants/materials, setting, methods
The time of pronuclei appearance and disappearance was recorded using the time-lapse incubation software. The number of oocytes exhibiting normal fertilisation (defined as the presence of two pronuclei) during 30 minute intervals from 15hpi to 20hpi was determined.
Main results and the role of chance
Between 15–17.5hpi the average number of oocytes exhibiting normal fertilisation was 98.19% with most oocytes having visible pronuclei at 16–16.5hpi (98.32%). At 18–18.5hpi the number of visible pronuclei falls to 95.53% and continues to fall to 87.02% at 19.5–20hpi meaning that over 3000 (11%) normally fertilised oocytes, within this cohort, would not be identified.
Limitations, reasons for caution
The conclusions of this investigation cannot be effectively extrapolated to IVF embryos as only ICSI embryos were used for the determination of the results.
Wider implications of the findings: The optimum time to perform fertilisation checks for oocytes cultured in standard incubation is 16.5hpi+/–0.5h. However, without the use of time-lapse incubation, the fertilisation of at least 2% of embryos that create a fetal heart will be missed, even if the fertilisation check is performed in the optimum window (16.5hpi+/–0.5h).
Trial registration number
Not applicable
Collapse
Affiliation(s)
- A Barrie
- CARE Fertility Ltd, CARE Fertility Chester, Chester, United Kingdom
| | - R Smith
- CARE Fertility Ltd, CARE Fertility UK, Nottingham, United Kingdom
| | - L Best
- CARE Fertility Ltd, CARE Fertility UK, Nottingham, United Kingdom
| | - N Davis
- CARE Fertility Ltd, CARE Fertility Nottingham, Nottingham, United Kingdom
| | - S Duffy
- CARE Fertility Ltd, CARE Fertility Manchester, Manchester, United Kingdom
| | - S Krokos
- CARE Fertility Ltd, CARE Fertility London, London, United Kingdom
| | - Y Lodge
- CARE Fertility Ltd, CARE Fertility Tunbridge Wells, Tunbridge Wells, United Kingdom
| | - S Montgomery
- CARE Fertility Ltd, CARE Fertility Manchester, Manchester, United Kingdom
| | - S O’Boyle
- CARE Fertility Ltd, CARE Fertility Dublin, Dublin, United Kingdom
| | - S Thirlby-Moore
- CARE Fertility Ltd, CARE Fertility Birmingham, Birmingham, United Kingdom
| | - B Whitten
- CARE Fertility Ltd, CARE Fertility Nottingham, Nottingham, United Kingdom
| | - A Campbell
- CARE Fertility Ltd, CARE Fertility UK, Nottingham, United Kingdom
| |
Collapse
|
17
|
Scott N, Barrie A, Smith R, Best L, Davis N, Duffy S, Krokos S, Lodge Y, Montgomery S, O’Boyle S, Thirlby-Moore S, Whitten B, Campbell A. P–792 The introduction of an embryo morphokinetics annotation quality assurance scheme across ten fertility clinics including 59 participants. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Can a group-wide quality assurance scheme be developed to effectively determine inter-operator agreement for morphokinetic parameters of interest.
Summary answer
Very strong agreement was found between all operators except for one, therefore this scheme effectively identified areas of improvement in inter-operator annotations.
What is known already
Where fertility clinics use embryo morphokinetics to determine viability potential, quality assurance of annotations is essential. Embryo selection algorithms rely on the manual determination of certain morphokinetic parameters. Variations in these parameters can lead to differences in the algorithm score attributed to an embryo thus potentially affecting its fate. It is vital that all embryologists involved in embryo annotation and selection are consistent with their annotation approach through regular quality assurance mechanisms.
Study design, size, duration
Each participant was required to annotate the same three embryos for morphokinetic parameters of interest, including tPB2, tPNf, t2 to t5, t8, tM, tSB, tB. Participants were also required to grade embryos at 68 hours post insemination (hpi), 112hpi and to assess additional parameters used for embryo selection or future investigations, such as the extent of morula compaction. The aim of this scheme is to release new distribution each quarter to ensure regular participation.
Participants/materials, setting, methods
All embryologists responsible for embryo annotation in a single, UK fertility group were enrolled onto the scheme. A total of 59 participants from 10 fertility clinics in the UK were included. Inter-operator agreement was assessed using two-way, mixed intraclass correlation coefficient (ICC) for consistency. Five categories of agreement were determined based on ICC score; very weak (0–0.2), weak (0.21–0.4), moderate (0.41–0.6), strong (0.61–0.8) and very strong (0.81–1.0).
Main results and the role of chance
Very strong agreement (0.81–1.0) was observed between all operators for all parameters assessed except for one operator who showed a weak agreement (0.21–0.4) with all other operators. Descriptive statistics revealed standard deviations (SD) ranging from 0.34 (t3) to 3.43 (t5). For each parameter the SD across the three assessed embryos ranged from 0.34–3.43; tPB2 (0.11–0.98), tPNf (2.06–4.40), t2 (0.22–0.80), t3 (0.16–0.70), t4 (0.39–0.65). t5 (2.40–5.44), t8 (0.33–2.72), tM (1.00–2.72), tSB (1.08–2.67), tB (1.12–1.81). These results indicate a high concordance with less subjective annotations such as the cell stage divisions and more variability with the subjective annotations such as the blastulation parameters. The concordance with less well practiced or understood annotations, such as extent of morula compaction, planar or tetrahedral orientation at the four cell stage as well as angle of extrusion of second polar body in relation to the first polar body, was poorer as indicated using descriptive statistics. This highlighted the need for experience in performing these annotations before drawing conclusions regarding their predictive nature in relation to an embryo’s viability.
Limitations, reasons for caution
The variability between more subjective parameters would be expected to be higher than others. The participation in these schemes can create false environments which do not reflect how an embryologist would usually score; they may spend longer on some decisions given the nature of the scheme.
Wider implications of the findings: Quality assurance of morphokinetic annotations across clinics utilising standardised selection models is crucial. Robust annotation policies and education programmes are essential in achieving consistent results between operators. Quality assurance schemes can identify individuals who lack consistency overall and can identify reliably annotated parameters to inform inclusion in embryo selection algorithms.
Trial registration number
Not applicable
Collapse
Affiliation(s)
- N Scott
- CARE Fertility UK, CARE Fertility Chester, Chester, United Kingdom
| | - A Barrie
- CARE Fertility UK, CARE Fertility Chester, Chester, United Kingdom
| | - R Smith
- CARE Fertility UK, CARE Fertility UK, Nottingham, United Kingdom
| | - L Best
- CARE Fertility UK, CARE Fertility UK, Nottingham, United Kingdom
| | - N Davis
- CARE Fertility UK, CARE Fertility Nottingham, Nottingham, United Kingdom
| | - S Duffy
- CARE Fertility UK, CARE Fertility Manchester, Manchester, United Kingdom
| | - S Krokos
- CARE Fertility UK, CARE Fertility London, London, United Kingdom
| | - Y Lodge
- CARE Fertility UK, CARE Fertility Tunbridge Wells, Tunbridge Wells, United Kingdom
| | - S Montgomery
- CARE Fertility UK, CARE Fertility Manchester, Manchester, United Kingdom
| | - S O’Boyle
- CARE Fertility UK, CARE Fertility Dublin, Dublin, United Kingdom
| | - S Thirlby-Moore
- CARE Fertility UK, CARE Fertility Birmingham, Birmingham, United Kingdom
| | - B Whitten
- CARE Fertility UK, CARE Fertility Nottingham, Nottingham, United Kingdom
| | - A Campbell
- CARE Fertility UK, CARE Fertility UK, Nottingham, United Kingdom
| |
Collapse
|
18
|
Chen NS, Boughton CK, Hartnell S, Fuchs J, Allen JM, Willinska ME, Thankamony A, de Beaufort C, Campbell FM, Fröhlich-Reiterer E, Hofer SE, Kapellen TM, Rami-Merhar B, Ghatak A, Randell TL, Besser REJ, Elleri D, Trevelyan N, Denvir L, Davis N, Gurnell E, Lindsay R, Morris D, Scott EM, Bally L, Thabit H, Leelarathna L, Evans ML, Murphy HR, Mader JK, Hovorka R. User Engagement With the CamAPS FX Hybrid Closed-Loop App According to Age and User Characteristics. Diabetes Care 2021; 44:e148-e150. [PMID: 34021021 PMCID: PMC8323184 DOI: 10.2337/dc20-2762] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Accepted: 04/06/2021] [Indexed: 02/03/2023]
Affiliation(s)
- Natalie S Chen
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, U.K
| | - Charlotte K Boughton
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, U.K. .,Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, U.K
| | - Sara Hartnell
- Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, U.K
| | - Julia Fuchs
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, U.K.,Department of Paediatrics, University of Cambridge, Cambridge, U.K
| | - Janet M Allen
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, U.K
| | - Malgorzata E Willinska
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, U.K
| | - Ajay Thankamony
- Department of Paediatrics, University of Cambridge, Cambridge, U.K
| | - Carine de Beaufort
- Diabetes Endocrinology Care Clinique Pédiatrique, Clinique Pédiatrique, Centre Hospitalier de Luxembourg, Luxembourg
| | - Fiona M Campbell
- Department of Paediatric Diabetes, Leeds Children's Hospital, Leeds, U.K
| | - Elke Fröhlich-Reiterer
- Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
| | - Sabine E Hofer
- Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria
| | - Thomas M Kapellen
- Hospital for Children and Adolescents, University of Leipzig, Leipzig, Germany
| | - Birgit Rami-Merhar
- Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
| | - Atrayee Ghatak
- Alder Hey Children's NHS Foundation Trust, Liverpool, U.K
| | | | - Rachel E J Besser
- Department of Paediatrics, University of Oxford, Oxford, U.K.,NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, U.K
| | | | | | | | - Nikki Davis
- Southampton Children's Hospital, Southampton, U.K
| | - Eleanor Gurnell
- Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, U.K
| | | | | | - Eleanor M Scott
- Department of Population and Clinical Sciences, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K
| | - Lia Bally
- Department of Diabetes, Endocrinology, Clinical Nutrition and Metabolism, Inselspital, Bern University Hospital, Bern, Switzerland
| | - Hood Thabit
- Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester, U.K
| | - Lalantha Leelarathna
- Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester, U.K
| | - Mark L Evans
- Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, U.K.,Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, U.K
| | - Helen R Murphy
- Norwich Medical School, University of East Anglia, Norwich, U.K
| | - Julia K Mader
- Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
| | | | | |
Collapse
|
19
|
MacCraith E, Cunnane E, Joyce M, Forde J, O'Brien F, Davis N. 181 Comparison of Synthetic Mesh Erosion and Chronic Pain Rates After Surgery for Pelvic Organ Prolapse and Stress Urinary Incontinence: A Systematic Review. Br J Surg 2021. [DOI: 10.1093/bjs/znab135.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Background
The aim of this study is to systematically compare rates of erosion and chronic pain after mesh insertion for pelvic organ prolapse (POP) and stress urinary incontinence (SUI) surgery.
Method
A systematic electronic search was performed on studies that evaluated the incidence of erosion and chronic pain after mesh insertion for POP or SUI. The primary outcome measurement was to compare mesh erosion and chronic pain rates for POP and SUI surgery.
Results
Twenty-six studies on 292,606 patients (n = 9077 for POP surgery and n = 283529 for SUI surgery) met inclusion criteria. The POP group were older (p < 0.0001) and had a lower BMI (p < 0.0001). Mesh erosion rates were significantly greater in the POP group compared to the SUI group (4% versus 1.9%) [OR 2.13; 95% CI 1.91-2.37; p < 0.0001]. The incidence of chronic pain was significantly greater in the POP group compared to the SUI group (6.7% versus 0.6%) [OR 11.02; 95% CI 8.15-14.9; p < 0.0001].
Conclusions
The risk of mesh erosion and chronic pain is significantly higher after surgery for POP compared to SUI. Since a higher volume of mesh is typically used for POP surgery this supports evidence for a dose-response relationship between the volume of mesh used and the erosion risk.
Collapse
Affiliation(s)
- E MacCraith
- Royal College of Surgeons in Ireland, Dublin, Ireland
- Blackrock Clinic, Dublin, Ireland
| | - E Cunnane
- Royal College of Surgeons in Ireland, Dublin, Ireland
| | - M Joyce
- Royal College of Surgeons in Ireland, Dublin, Ireland
| | - J Forde
- Royal College of Surgeons in Ireland, Dublin, Ireland
- Blackrock Clinic, Dublin, Ireland
| | - F O'Brien
- Royal College of Surgeons in Ireland, Dublin, Ireland
| | - N Davis
- Royal College of Surgeons in Ireland, Dublin, Ireland
- Blackrock Clinic, Dublin, Ireland
| |
Collapse
|
20
|
Shaunak M, Byrne CD, Davis N, Afolabi P, Faust SN, Davies JH. Non-alcoholic fatty liver disease and childhood obesity. Arch Dis Child 2021; 106:3-8. [PMID: 32409495 DOI: 10.1136/archdischild-2019-318063] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Revised: 04/24/2020] [Accepted: 04/25/2020] [Indexed: 12/11/2022]
Abstract
Non-alcoholic fatty liver disease (NAFLD) in children and adolescents has an estimated prevalence of 36.1% in the context of obesity. This figure is anticipated to increase in conjunction with the global obesity epidemic. Worryingly, NAFLD in childhood persisting into adulthood is likely to be harmful, contributing to significant hepatic and extrahepatic morbidities. Early disease detection is required, although the optimum timing, frequency and mode of screening remains undetermined. While the efficacy of several medications, antioxidants, fatty acid supplements and probiotics has been investigated in children, healthy eating and physical activity remain the only prevention and treatment strategies for paediatric NAFLD. This short review discusses the epidemiology, diagnosis, pathogenesis and management of NAFLD in childhood obesity.
Collapse
Affiliation(s)
- Meera Shaunak
- Department of Paediatric Endocrinology, University Hospital Southampton NHS Foundation Trust, Southampton, UK
| | - Christopher D Byrne
- Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.,NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK
| | - Nikki Davis
- Department of Paediatric Endocrinology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.,Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK
| | - Paul Afolabi
- Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.,NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK
| | - Saul N Faust
- Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.,NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.,NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK
| | - Justin Huw Davies
- Department of Paediatric Endocrinology, University Hospital Southampton NHS Foundation Trust, Southampton, UK .,Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK
| |
Collapse
|
21
|
Cullivan O, O’Meara S, Cheema I, Quinlan M, Davis N, McLornan L. Improving the Quality of Renal Colic Referrals to Urology Services: A Full Cycle Departmental Audit. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)35229-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
22
|
O’Meara S, Byrnes K, Ríogh AA, Little D, Davis N. Establishment of an automated electronic registry for bladder cancer surveillance: Completing the audit cycle. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)35248-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
23
|
Msaouel P, Siefker-Radtke A, Sweis R, Mao S, Rosenberg J, Vaishampayan U, Kalebasty AR, Pili R, Bupathi M, Nordquist L, Shaffer D, Davis N, Zhang T, Gandhi S, Christensen J, Shazer R, Yan X, Winter M, Der-Torossian H, Iyer GV. 705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.777] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
24
|
Mac Craith E, Jose Farias Correa Do Amaral R, Cunnane E, Joyce M, O’Brien F, Davis N. Development and investigation of a tissue-engineered biodegradable mesh for the treatment of Stress Urinary Incontinence (SUI) in female patients. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)32973-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
25
|
Qu L, Howard T, Poyet C, Davis N, Bolton D, Al-Shawi M, Jack G. Does biopsy approach affect histopathology grade concordance from biopsy to prostatectomy? An Australian analysis. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)32663-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
26
|
Secor A, Macauley R, Stan L, Kagone M, Sidikiba S, Sow S, Aronovich D, Litvin K, Davis N, Alva S, Sanderson J. Mental health among Ebola survivors in Liberia, Sierra Leone and Guinea: results from a cross-sectional study. BMJ Open 2020; 10:e035217. [PMID: 32461296 PMCID: PMC7259862 DOI: 10.1136/bmjopen-2019-035217] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
OBJECTIVES To describe the prevalence and correlates of depression and anxiety among adult Ebola virus disease (EVD) survivors in Liberia, Sierra Leone and Guinea. DESIGN Cross-sectional. SETTING One-on-one surveys were conducted in EVD-affected communities in Liberia, Sierra Leone and Guinea in early 2018. PARTICIPANTS 1495 adult EVD survivors (726 male, 769 female). PRIMARY AND SECONDARY OUTCOME MEASURES Patient Health Questionnaire-9 (PHQ-9) depression scores and Generalised Anxiety Disorder-7 (GAD-7) scores. RESULTS Prevalence and severity of depression and anxiety varied across the three countries. Sierra Leone had the highest prevalence of depression, with 22.0% of participants meeting the criteria for a tentative diagnosis of depression, compared with 20.2% in Liberia and 13.0% in Guinea. Sierra Leone also showed the highest prevalence of anxiety, with 10.7% of participants meeting criteria for generalized anxiety disorder (GAD-7 score ≥10), compared with 9.9% in Liberia and 4.2% in Guinea. Between one-third and one-half of respondents reported little interest or pleasure in doing things in the previous 2 weeks (range: 47.0% in Liberia to 37.6% in Sierra Leone), and more than 1 in 10 respondents reported ideation of self-harm or suicide (range: 19.4% in Sierra Leone to 10.4% in Guinea). Higher depression and anxiety scores were statistically significantly associated with each other and with experiences of health facility-based stigma in all three countries. Other associations between mental health scores and respondent characteristics varied across countries. CONCLUSIONS Our results indicate that both depression and anxiety are common among EVD survivors in Liberia, Sierra Leone and Guinea, but that there is country-level heterogeneity in prevalence, severity and correlates of these conditions. All three countries should work to make mental health services available for survivors, and governments and organisations should consider the intersection between EVD-related stigma and mental health when designing programmes and training healthcare providers.
Collapse
Affiliation(s)
- Andrew Secor
- JSI Research and Training Institute Inc, Monrovia, Liberia
- Department of Global Health, University of Washington, Seattle, Washington, USA
| | - Rose Macauley
- JSI Research and Training Institute Inc, Monrovia, Liberia
| | - Laurentiu Stan
- JSI Research and Training Institute Inc, Freetown, Sierra Leone
| | - Meba Kagone
- JSI Research and Training Institute Inc, Conakry, Guinea
| | | | - Sadou Sow
- JSI Research and Training Institute Inc, Conakry, Guinea
| | - Dana Aronovich
- JSI Research and Training Institute Inc, Arlington, Virginia, USA
| | - Kate Litvin
- JSI Research and Training Institute Inc, Arlington, Virginia, USA
| | - Nikki Davis
- JSI Research and Training Institute Inc, Arlington, Virginia, USA
| | - Soumya Alva
- JSI Research and Training Institute Inc, Arlington, Virginia, USA
| | - Jeff Sanderson
- JSI Research and Training Institute Inc, Arlington, Virginia, USA
| |
Collapse
|
27
|
Al-Khamis A, Warner C, Park J, Marecik S, Davis N, Mellgren A, Nordenstam J, Kochar K. Modified frailty index predicts early outcomes after colorectal surgery: an ACS-NSQIP study. Colorectal Dis 2019; 21:1192-1205. [PMID: 31162882 DOI: 10.1111/codi.14725] [Citation(s) in RCA: 66] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2018] [Accepted: 05/14/2019] [Indexed: 02/08/2023]
Abstract
AIM Frailty is defined as a decrease in physiological reserve with increased risk of morbidity following significant physiological stressors. This study examines the predictive power of the five-item modified frailty index (5-mFI) in predicting outcomes in colorectal surgery patients. METHODS The American College of Surgeons National Surgical Quality Improvement Program Database was queried from 2011 to 2016 to determine the predictive power of 5-mFI in patients who had colorectal surgery. RESULTS Of 295 490 patients, 45.8% had a score of 0, 36.2% had a score of 1 and 18% had a score of ≥ 2. On univariate analysis, frailer patients had significantly greater incidences for overall morbidity, serious morbidity, mortality, prolonged length of hospital stay, discharge to a facility other than home, reoperation and unplanned readmission. These findings were consistent on multivariate analysis where the frailest patients had greater odds of postoperative overall morbidity (OR 1.39; 95% CI 1.35-1.43), serious morbidity (OR 1.39; 95% CI 1.33-1.45), mortality (OR 2.00; 95% CI 1.87-2.14), prolonged length of hospital stay (OR 1.24; 95% CI 1.20-1.27), discharge destination to a facility other than home (OR 2.80; 95% CI 2.70-2.90), reoperation (OR 1.17; 95% CI 1.11-1.23) and unplanned readmission (OR 1.31; 95% CI 1.26-1.36). Weighted kappa statistics showed strong agreement between the 5-mFI and 11-mFI (kappa = 0.987, P < 0.001). CONCLUSIONS The 5-mFI is a valid and easy to use predictor of 30-day postoperative outcomes after colorectal surgery. This tool may guide the surgeon to proactively recognize frail patients to instigate interventions to optimize them preoperatively.
Collapse
Affiliation(s)
- A Al-Khamis
- Faculty of Medicine, Division of Surgery, Kuwait University, Kuwait, Kuwait.,Division of Colon and Rectal Surgery, Advocate Lutheran General Hospital, Park Ridge, Illinois, USA
| | - C Warner
- Division of Colon and Rectal Surgery, University of Illinois at Chicago, Chicago, Illinois, USA
| | - J Park
- Division of Colon and Rectal Surgery, Advocate Lutheran General Hospital, Park Ridge, Illinois, USA
| | - S Marecik
- Division of Colon and Rectal Surgery, Advocate Lutheran General Hospital, Park Ridge, Illinois, USA
| | - N Davis
- Division of Colon and Rectal Surgery, University of Illinois at Chicago, Chicago, Illinois, USA
| | - A Mellgren
- Division of Colon and Rectal Surgery, University of Illinois at Chicago, Chicago, Illinois, USA
| | - J Nordenstam
- Division of Colon and Rectal Surgery, University of Illinois at Chicago, Chicago, Illinois, USA
| | - K Kochar
- Division of Colon and Rectal Surgery, Advocate Lutheran General Hospital, Park Ridge, Illinois, USA
| |
Collapse
|
28
|
Wei C, Candler T, Davis N, Elson R, Crabtree N, Stevens M, Crowne E. Bone Mineral Density Corrected for Size in Childhood Leukaemia Survivors Treated with Haematopoietic Stem Cell Transplantation and Total Body Irradiation. Horm Res Paediatr 2018; 89:246-254. [PMID: 29804121 DOI: 10.1159/000487996] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Accepted: 02/26/2018] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Childhood leukaemia survivors treated with haematopoietic stem cell transplantation and total body irradiation (HSCT-TBI) have multiple risk factors for reduced bone mineral density (BMD) and growth failure; hence, BMD assessment must take body size into consideration. This study aimed to evaluate size-corrected BMD in leukaemia survivors treated with and without HSCT-TBI. METHODS Childhood leukaemia survivors treated with HSCT-TBI (n = 35), aged 17.3 (10.5-20.9) years, were compared with those treated with chemotherapy only, (n = 16) aged 18.5 (16.1-20.9) years, and population references. Outcome measures included anthropometric measurements and BMD by dual-energy X-ray absorptiometry. BMD was corrected for size as bone mineral apparent density (BMAD). Statistical analysis was performed by 1- and 2-sample t tests as well as regression analysis (5% significance). RESULTS HSCT-TBI survivors were lighter and shorter with reduced spinal heights compared with chemotherapy-only subjects and population references. Compared with population references, HSCT-TBI survivors showed lower BMD standard deviation scores (SDS) (p = 0.008), but no difference in BMAD-SDS, and chemotherapy-only survivors showed no differences in neither BMD-SDS nor BMAD-SDS. All HSCT-TBI participants with BMD-SDS <-2 had BMAD-SDS >-2. BMAD-SDS was negatively associated with age (r = -0.38, p = 0.029) in HSCT-TBI survivors. CONCLUSIONS Size-corrected BMD are normal in HSCT-TBI survivors in young adulthood, but may reduce overtime. BMD measurements should be corrected for size in these patients to be clinically meaningful.
Collapse
Affiliation(s)
- Christina Wei
- Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.,University of Bristol, Bristol, United Kingdom.,St George's University, NHS Foundation Trust, Bristol, United Kingdom
| | - Toby Candler
- Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.,University of Bristol, Bristol, United Kingdom
| | - Nikki Davis
- Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.,University of Bristol, Bristol, United Kingdom.,University Hospital Southampton, NHS Foundation Trust, Southampton, United Kingdom
| | - Ruth Elson
- Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
| | - Nicola Crabtree
- Birmingham Women's and Children's Hospital, Birmingham, United Kingdom
| | | | - Elizabeth Crowne
- Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.,University of Bristol, Bristol, United Kingdom
| |
Collapse
|
29
|
Tang J, Davis N, Corbett A, Chinula L, Msika A, Cottrell M, Tegha G, Stanczyk F, Hurst S, Hosseinipour M, Haddad L, Kourtis A. Effect of efavirenz antitretroviral therapy on levonorgestrel concentrations among levonorgestrel implant users over 3 years of concomitant use. Contraception 2018. [DOI: 10.1016/j.contraception.2018.07.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
30
|
Laver TW, Patel KA, Colclough K, Curran J, Dale J, Davis N, Savage DB, Flanagan SE, Ellard S, Hattersley AT, Weedon MN. PLIN1 Haploinsufficiency Is Not Associated With Lipodystrophy. J Clin Endocrinol Metab 2018; 103:3225-3230. [PMID: 30020498 PMCID: PMC6126890 DOI: 10.1210/jc.2017-02662] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/07/2017] [Accepted: 07/12/2018] [Indexed: 11/19/2022]
Abstract
CONTEXT Monogenic partial lipodystrophy is a genetically heterogeneous disease where only variants with specific genetic mechanisms are causative. Three heterozygous protein extending frameshift variants in PLIN1 have been reported to cause a phenotype of partial lipodystrophy and insulin resistance. OBJECTIVE We investigated if null variants in PLIN1 cause lipodystrophy. METHODS As part of a targeted sequencing panel test, we sequenced PLIN1 in 2208 individuals. We also investigated the frequency of PLIN1 variants in the gnomAD database, and the type 2 diabetes knowledge portal. RESULTS We identified 6/2208 (1 in 368) individuals with a PLIN1 null variant. None of these individuals had clinical or biochemical evidence of overt lipodystrophy. Additionally, 14/17,000 (1 in 1214) individuals with PLIN1 null variants in the type 2 diabetes knowledge portal showed no association with biomarkers of lipodystrophy. PLIN1 null variants occur too frequently in gnomAD (126/138,632; 1 in 1100) to be a cause of rare overt monogenic partial lipodystrophy. CONCLUSIONS Our study suggests that heterozygous variants that are predicted to result in PLIN1 haploinsufficiency are not a cause of familial partial lipodystrophy and should not be reported as disease-causing variants by diagnostic genetic testing laboratories. This finding is in keeping with other known monogenic causes of lipodystrophy, such as PPARG and LMNA, where only variants with specific genetic mechanisms cause lipodystrophy.
Collapse
Affiliation(s)
- Thomas W Laver
- Institute of Biomedical & Clinical Science, University of Exeter, Exeter, United Kingdom
- Correspondence and Reprint Requests: Thomas W. Laver, PhD, Institute of Biomedical & Clinical Science, RILD Building Level 3, Royal Devon & Exeter Hospital, Barrack Road, Exeter, EX2 5DW, United Kingdom. E-mail:
| | - Kashyap A Patel
- Institute of Biomedical & Clinical Science, University of Exeter, Exeter, United Kingdom
| | - Kevin Colclough
- Department of Molecular Genetics, Royal Devon & Exeter NHS Foundation Trust, Exeter, United Kingdom
| | - Jacqueline Curran
- Department of Endocrinology, Princess Margaret Hospital, Perth, Western Australia, Australia
| | - Jane Dale
- The Dudley Group NHS Foundation Trust, Dudley, United Kingdom
| | - Nikki Davis
- University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
| | - David B Savage
- The University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, United Kingdom
- The National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - Sarah E Flanagan
- Institute of Biomedical & Clinical Science, University of Exeter, Exeter, United Kingdom
| | - Sian Ellard
- Institute of Biomedical & Clinical Science, University of Exeter, Exeter, United Kingdom
- Department of Molecular Genetics, Royal Devon & Exeter NHS Foundation Trust, Exeter, United Kingdom
| | - Andrew T Hattersley
- Institute of Biomedical & Clinical Science, University of Exeter, Exeter, United Kingdom
| | - Michael N Weedon
- Institute of Biomedical & Clinical Science, University of Exeter, Exeter, United Kingdom
| |
Collapse
|
31
|
Bowley DM, Davis N, Ballard M, Orr L, Eddleston J. Military assistance to the civil authority: medical liaison with the Manchester clinicians after the Arena bombing. BMJ Mil Health 2018; 166:76-79. [DOI: 10.1136/jramc-2018-000944] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2018] [Revised: 06/28/2018] [Accepted: 06/28/2018] [Indexed: 11/04/2022]
Abstract
UK Defence Medical Services’ personnel have experienced an intense exposure to patients injured during war over the last decade and a half. As some bitter lessons of war surgery were relearned and innovative practices introduced, outcomes for patients impr oved consistently as experience accumulated. The repository of many of the enduring lessons learnt at the Role 4 echelon of care remain at the Queen Elizabeth Hospital Birmingham (QEHB), with the National Health Service and Defence Medical Services personnel who treated the returning casualties. On 22 May 2017, a terrorist detonated an improvised explosive device at the Manchester Arena, killing 22 and wounding 159 people. In the aftermath of the event, QEHB was requested to provide support to the Manchester clinicians and teleconferencing and then two clinical visits were arranged. This short report describes the nature of the visits, outlines the principles of Military Aid to the Civil Authority and looks to the future role of the Defence Medical Services in planning and response to UK terrorism events.
Collapse
|
32
|
Abstract
Non-pharmacological techniques in the management of hypertension have been shown to be beneficial. This pilot study was set up to examine how often routine advice was given with respect to weight reduction and/or lifestyle adjustments, and whether it was heeded. Three-quarters of the 69 patients in the study smoked or were overweight but only half of the smokers recalled advice to stop. One-fifth of the patients were apparently not told to lose weight. Only one-third recalled being told to reduce alcohol intake. Lifestyle counselling and the management of hypertension in this small study appeared to be not completely effective for various reasons. It is likely to be cheaper and more satisfactory than medication alone or as an adjunct and its application deserves further study.
Collapse
Affiliation(s)
- J Marley
- Department of Cardiology, St Peter's District Hospital, Chertsey, Surrey
| | | | | |
Collapse
|
33
|
Talbot C, Davis N, Majid I, Young M, Bouamra O, Lecky FE, Jones S. Fractures of the femoral shaft in children: national epidemiology and treatment trends in England following activation of major trauma networks. Bone Joint J 2018; 100-B:109-118. [PMID: 29305459 DOI: 10.1302/0301-620x.100b1.bjj-2016-1315.r3] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
AIMS The aim of this study was to describe the epidemiology of closed isolated fractures of the femoral shaft in children, and to compare the treatment and length of stay (LOS) between major trauma centres (MTCs) and trauma units (TUs) in England. PATIENTS AND METHODS National data were obtained from the Trauma and Audit Research Network for all isolated, closed fractures of the femoral shaft in children from birth to 15 years of age, between 2012 and 2015. Age, gender, the season in which the fracture occurred, non-accidental injury, the mechanism of injury, hospital trauma status, LOS and type of treatment were recorded. RESULTS A total of 1852 fractures were identified. The mean annual incidence was 5.82 per 100 000 children (95% confidence interval (CI) 5.20 to 6.44). The age of peak incidence was two years for both boys and girls; this decreased with increasing age. Children aged four to six years treated in MTCs were more likely to be managed with open reduction and internal fixation compared with those treated in TUs (odds ratio 3.20; 95% CI 1.12 to 9.14; p = 0.03). The median LOS was significantly less in MTCs than in TUs for children aged between 18 months and three years treated in both a spica (p = 0.005) and traction (p = 0.0004). CONCLUSION This study highlights the current national trends in the management of closed isolated fractures of the femoral shaft in children following activation of major trauma networks in 2012. Future studies focusing on the reasons for the differences which have been identified may help to achieve more consistency in the management of these injuries across the trauma networks. Cite this article: Bone Joint J 2018;100-B:109-18.
Collapse
Affiliation(s)
- C Talbot
- Royal Manchester Children's Hospital, Oxford Road, Manchester M13 9WL, UK
| | - N Davis
- Royal Manchester Children's Hospital, Oxford Road, Manchester M13 9WL, UK
| | - I Majid
- Royal Manchester Children's Hospital
| | - M Young
- University of Manchester, Trauma Audit and Research Network, Salford, Manchester M6 8HD, UK
| | - O Bouamra
- University of Manchester, Trauma Audit and Research Network, Salford, Manchester M6 8HD, UK
| | - F E Lecky
- University of Sheffield, School of Health and Related Research, Western Bank, Sheffield S10 2TN, UK
| | - S Jones
- Royal Manchester Children's Hospital
| |
Collapse
|
34
|
Abstract
This article describes a new technique for quantifying creative collaboration and applies it to the user study evaluation of a co-creative drawing agent. We present a cognitive framework called
creative sense-making
that provides a new method to visualize and quantify the interaction dynamics of creative collaboration, for example, the rhythm of interaction, style of turn taking, and the manner in which participants are mutually making sense of a situation. The creative sense-making framework includes a qualitative coding technique, interaction coding software, an analysis method, and the cognitive theory behind these applications. This framework and analysis method are applied to empirical studies of the
Drawing Apprentice
collaborative sketching system to compare human collaboration with a co-creative AI agent vs. a Wizard of Oz setup. The analysis demonstrates how the proposed technique can be used to analyze interaction data using continuous functions (e.g., integrations and moving averages) to measure and evaluate how collaborations unfold through time.
Collapse
Affiliation(s)
- N. Davis
- Georgia Institute of Technology, Atlanta, GA
| | - C. Hsiao
- Georgia Institute of Technology, Atlanta, GA
| | - K. Y. Singh
- Georgia Institute of Technology, Atlanta, GA
| | - B. Lin
- Georgia Institute of Technology, Atlanta, GA
| | | |
Collapse
|
35
|
Carding SR, Davis N, Hoyles L. Review article: the human intestinal virome in health and disease. Aliment Pharmacol Ther 2017; 46:800-815. [PMID: 28869283 PMCID: PMC5656937 DOI: 10.1111/apt.14280] [Citation(s) in RCA: 145] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2017] [Revised: 04/07/2017] [Accepted: 08/07/2017] [Indexed: 02/06/2023]
Abstract
BACKGROUND The human virome consists of animal-cell viruses causing transient infections, bacteriophage (phage) predators of bacteria and archaea, endogenous retroviruses and viruses causing persistent and latent infections. High-throughput, inexpensive, sensitive sequencing methods and metagenomics now make it possible to study the contribution dsDNA, ssDNA and RNA virus-like particles make to the human virome, and in particular the intestinal virome. AIM To review and evaluate the pioneering studies that have attempted to characterise the human virome and generated an increased interest in understanding how the intestinal virome might contribute to maintaining health, and the pathogenesis of chronic diseases. METHODS Relevant virome-related articles were selected for review following extensive language- and date-unrestricted, electronic searches of the literature. RESULTS The human intestinal virome is personalised and stable, and dominated by phages. It develops soon after birth in parallel with prokaryotic communities of the microbiota, becoming established during the first few years of life. By infecting specific populations of bacteria, phages can alter microbiota structure by killing host cells or altering their phenotype, enabling phages to contribute to maintaining intestinal homeostasis or microbial imbalance (dysbiosis), and the development of chronic infectious and autoimmune diseases including HIV infection and Crohn's disease, respectively. CONCLUSIONS Our understanding of the intestinal virome is fragmented and requires standardised methods for virus isolation and sequencing to provide a more complete picture of the virome, which is key to explaining the basis of virome-disease associations, and how enteric viruses can contribute to disease aetiologies and be rationalised as targets for interventions.
Collapse
Affiliation(s)
- S. R. Carding
- Norwich Medical SchoolUniversity of East AngliaNorwichUK,The Gut Health and Food Safety Research ProgrammeThe Quadram InstituteNorwich Research ParkNorwichUK
| | - N. Davis
- Norwich Medical SchoolUniversity of East AngliaNorwichUK
| | - L. Hoyles
- Department of Surgery and CancerImperial College LondonLondonUK
| |
Collapse
|
36
|
Bradley B, Middleton S, Davis N, Williams M, Stocker M, Hockings M, Isaac DL. Discharge on the day of surgery following unicompartmental knee arthroplasty within the United Kingdom NHS. Bone Joint J 2017; 99-B:788-792. [PMID: 28566398 DOI: 10.1302/0301-620x.99b6.bjj-2016-0540.r2] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2016] [Accepted: 01/27/2017] [Indexed: 11/05/2022]
Abstract
AIMS Unicompartmental knee arthroplasty (UKA) has been successfully performed in the United States healthcare system on outpatients. Despite differences in healthcare structure and financial environment, we hypothesised that it would be feasible to replicate this success and perform UKA with safe day of surgery discharge within the NHS, in the United Kingdom. This has not been reported in any other United Kingdom centres. PATIENTS AND METHODS We report our experience of implementing a pathway to allow safe day of surgery discharge following UKA. Data were prospectively collected on 72 patients who underwent UKA as a day case between December 2011 and September 2015. RESULTS A total of 61 patients (85%) were discharged on the same day. The most common reason for failure was logistical; five patients had their operation too late in the day. Three patients failed to mobilise safely, two had inadequate control of pain and one had a leaking wound. The mean length of stay for those who were not discharged on the same day was 1.2 nights (1 to 3). During the same time, 58 patients underwent planned inpatient UKA, as they were deemed inappropriate for discharge on the day of surgery. However, three of these were safely discharged on the same day. Follow-up data, 24 hours post-operatively, were available for 70 patients; 51 (73%) reported no or mild pain, 14 (20%) had moderate pain and five (7%) had severe pain. There were no re-admissions. All patients had a high level of satisfaction. CONCLUSION We found that patients can be safely and effectively discharged on the day of surgery after UKA, with high levels of satisfaction. This clearly offers improved management of resources and financial savings to healthcare trusts. Cite this article: Bone Joint J 2017;99-B:788-92.
Collapse
Affiliation(s)
- B Bradley
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Lowes Bridge, Torquay TQ2 7AA, UK
| | - S Middleton
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Lowes Bridge, Torquay TQ2 7AA, UK
| | - N Davis
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Lowes Bridge, Torquay TQ2 7AA, UK
| | - M Williams
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Lowes Bridge, Torquay TQ2 7AA, UK
| | - M Stocker
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Lowes Bridge, Torquay TQ2 7AA, UK
| | - M Hockings
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Lowes Bridge, Torquay TQ2 7AA, UK
| | - D L Isaac
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Lowes Bridge, Torquay TQ2 7AA, UK
| |
Collapse
|
37
|
Wei C, Unsworth R, Davis N, Cox R, Bradley K, Stevens M, Crowne E. Survivors of childhood leukaemia treated with haematopoietic stem cell transplantation and total body irradiation should undergo screening for diabetes by oral glucose tolerance tests. Diabet Med 2016; 33:1347-51. [PMID: 26757409 DOI: 10.1111/dme.13060] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/07/2016] [Indexed: 11/29/2022]
Abstract
AIMS Childhood cancer survivors treated with haematopoietic stem cell transplantation (HSCT) and total body irradiation are at an increased risk of developing diabetes early in life due to insulin resistance and β-cell dysfunction, but the optimal screening method is unknown. The National Institute for Health and Care Excellence guidelines for community diabetes screening recommend using fasting glucose ≥ 7 mmol/l and/or HbA1c ≥ 48 mmol/mol (6.5%) for diagnosis and, fasting glucose 5.5-6.9 mmol/l or HbA1c 42-47 mmol/mol (6-6.5%) to indicate high risk. This study aimed to evaluate the sensitivities of fasting glucose and HbA1c in the diagnosis of diabetes and impaired glucose tolerance in childhood HSCT survivors. METHOD The patients were 35 (male = 19) HSCT survivors from a single UK centre under follow-up from 2006 to 2013. Patients had a median age (range) of 19.2 (13.1-26.2) years and had been treated for acute lymphoblastic (n = 31) or myeloid (n = 4) leukaemia when aged 7.8 (2.4-16.7) years. The outcome measures were oral glucose tolerance test (OGTT), fasting glucose and HbA1c . RESULTS OGTT identified 6 patients with diabetes (120-min glucose ≥ 11.1 mmol/l), 12 with impaired glucose tolerance (120-min glucose 7.8-11.0 mmol/l) and 2 with impaired fasting glucose (≥ 7 mmol/l). Fasting glucose ≥ 7 mmol/l or HbA1c ≥ 48 mmol/mol identified two of the six patients with diabetes diagnosed on OGTT. Fasting glucose ≥ 5.5 mmol/l and HbA1c ≥ 42 mmol/mol identified three and two patients, respectively, with diabetes. Only 1 of 12 patients with impaired glucose tolerance had a fasting glucose ≥ 5.5 mmol/l and none had HbA1c ≥ 42 mmol/mol (≥ 6%). CONCLUSIONS The fasting glucose and HbA1c cut-offs used in UK population screening only identified one-third of HSCT survivors with diabetes and do not identify those at risk. Diabetes screening in HSCT survivors requires standard OGTTs.
Collapse
Affiliation(s)
- C Wei
- Bristol Royal Hospital for Children, Bristol, UK
| | - R Unsworth
- Bristol Royal Hospital for Children, Bristol, UK
| | - N Davis
- Bristol Royal Hospital for Children, Bristol, UK
| | - R Cox
- Bristol Royal Hospital for Children, Bristol, UK
| | - K Bradley
- Bristol Royal Hospital for Children, Bristol, UK
| | - M Stevens
- Bristol Royal Hospital for Children, Bristol, UK
| | - E Crowne
- Bristol Royal Hospital for Children, Bristol, UK.
| |
Collapse
|
38
|
Abstract
Concerns with pubertal development are common and can cause considerable distress to patients and their carers. Many presentations reflect normal variations of pubertal timing and primarily require reassurance, although patients may opt for interventions. Other presentations need active management to avoid significant adverse effects on growth and psychosocial development. All should undergo careful assessment, particularly as some children or adolescents presenting with abnormalities in pubertal timing may have serious pathology which requires urgent investigations and treatment. This review describes the appropriate investigations and their interpretation for young people presenting with disorders in pubertal timing.
Collapse
Affiliation(s)
- Christina Wei
- Department of Paediatric Endocrinology, St George’s University Hospitals NHS Foundation Trust, London, UK
| | - Nikki Davis
- Department of Paediatric Endocrinology, University Hospital Southampton, NHS Foundation Trust, Hampshire, UK
| | - John Honour
- Institute of Women's Health, University College London, London, UK
| | - Elizabeth Crowne
- Department of Paediatric Endocrinology, Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
| |
Collapse
|
39
|
Davis N, Jyothirmayi R. Choice of Radiotherapy Regime in Patients Undergoing Mastectomy and Immediate Reconstructive Surgery. Clin Oncol (R Coll Radiol) 2016. [DOI: 10.1016/j.clon.2016.01.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
40
|
Abstract
There is good evidence that morbidity and mortality increase for young persons (YP) following the move from paediatric to adult services. Studies show that effective transition between paediatric and adult care improves long-term outcomes. Many of the issues faced by young people across subspecialties with a long-term condition are generic. This article sets out some of the obstacles that have delayed the implementation of effective transition. It reports on a successful generic transition programme 'Ready Steady Go' that has been implemented within a large National Health Service teaching hospital in the UK, with secondary and tertiary paediatric services, where it is now established as part of routine care.
Collapse
Affiliation(s)
- Arvind Nagra
- Department of Paediatric Nephro-Urology, Southampton Children's Hospital, Southampton, UK
| | - Patricia M McGinnity
- Department of Paediatric Respiratory Medicine, Southampton Children's Hospital, Southampton, UK
| | - Nikki Davis
- Department of Paediatric Endocrinology and Diabetes, Southampton Children's Hospital, Southampton, UK
| | - Anthony P Salmon
- Department of Adult Congenital Heart Medicine, University Hospitals Southampton, Southampton, UK
| |
Collapse
|
41
|
Strizki J, Graham D, Lu M, Wu G, Breslin M, Davis N, Escandon E, Fayadat-Dilman L, Zheng Y, Barnard R, Garbaccio R, Manibusan A, Bhowmik S, Gately D, Sun Y, Gorman D. Limitations of employing antibody drug conjugates (ADCs) for targeting HIV infected cells as a strategy for hiv cure. J Virus Erad 2015. [DOI: 10.1016/s2055-6640(20)31408-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
42
|
Jaacks L, Ma Y, Davis N, Delahanty L, Mayer-Davis E, Franks P, Brown-Friday J, Isonaga M, Kriska A, Venditti E, Wylie-Rosett J. Long-term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabet Med 2014; 31:1631-42. [PMID: 24824893 PMCID: PMC4307949 DOI: 10.1111/dme.12500] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2013] [Revised: 02/03/2014] [Accepted: 05/09/2014] [Indexed: 12/20/2022]
Abstract
AIMS To compare change in dietary intake, with an emphasis on food groups and food intake behaviour, over time across treatment arms in a diabetes prevention trial and to assess the differences in dietary intake among demographic groups within treatment arms. METHODS Data are from the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Participants were randomized to a lifestyle intervention (n = 1079), metformin (n = 1073) or placebo (n = 1082) for an average of 3 years, after which the initial results regarding the benefits of the lifestyle intervention were released and all participants were offered a modified lifestyle intervention. Dietary intake was assessed using a food frequency questionnaire at baseline and at 1, 5, 6 and 9 years after randomization. RESULTS Compared with the metformin and placebo arms, participants in the lifestyle arm maintained a lower total fat and saturated fat and a higher fibre intake up to 9 years after randomization and lower intakes of red meat and sweets were maintained for up to 5 years. Younger participants had higher intakes of poultry and lower intakes of fruits compared with their older counterparts, particularly in the lifestyle arm. Black participants tended to have lower dairy and higher poultry intakes compared with white and Hispanic participants. In the lifestyle arm, men tended to have higher grain, fruit and fish intakes than women. CONCLUSIONS Changes in nutrient intake among participants in the lifestyle intervention were maintained for up to 9 years. Younger participants reported more unhealthy diets over time and thus may benefit from additional support to achieve and maintain dietary goals.
Collapse
Affiliation(s)
- L.M. Jaacks
- Department of Nutrition, University of North Carolina, Chapel Hill,
NC
| | - Y. Ma
- George Washington University, Washington, DC
| | - N. Davis
- Albert Einstein College of Medicine, Bronx, NY
| | - L.M. Delahanty
- Massachusetts General Hospital and Harvard Medical School, Boston,
MA
| | - E.J. Mayer-Davis
- Department of Nutrition, University of North Carolina, Chapel Hill,
NC
- Department of Medicine, University of North Carolina, Chapel Hill,
NC
| | - P.W. Franks
- Lund University, Malmö, Sweden and Harvard School of Public
Health, Boston, MA
| | | | | | | | | | - J. Wylie-Rosett
- Albert Einstein College of Medicine, Bronx, NY
- Correspondence to
| |
Collapse
|
43
|
Abstract
Periprosthetic fractures around total knee replacements were first reported more than 30 years ago. They are becoming more common. Various associated risk factors have been described. Treatment options for femoral fractures around total knee replacements include non-operative management, locked plates, retrograde intramedullary nails and revision arthroplasty. Periprosthetic fractures of the tibia and patella are also described, but are less common. This review article provides an overview of the epidemiology and frequency of periprosthetic fractures around total knee replacement, their initial assessment and the current treatment options available.
Collapse
Affiliation(s)
- N Davis
- Department of Trauma and Orthopaedics, Torbay Hospital, Torbay, UK
| | - G Higgins
- Department of Trauma and Orthopaedics, Torbay Hospital, Torbay, UK
| |
Collapse
|
44
|
Greven DEA, Cohen ES, Gerlag DM, Campbell J, Woods J, Davis N, van Nieuwenhuijze A, Lewis A, Heasmen S, McCourt M, Corkill D, Dodd A, Elvin J, Statache G, Wicks IP, Anderson IK, Nash A, Sleeman MA, Tak PP. Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis. Ann Rheum Dis 2014; 74:1924-30. [PMID: 24936585 PMCID: PMC4602263 DOI: 10.1136/annrheumdis-2014-205234] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2014] [Accepted: 05/01/2014] [Indexed: 01/19/2023]
Abstract
Objective Previous work has suggested that the granulocyte macrophage colony stimulating factor (GM-CSF)–GM-CSF receptor α axis (GM-CSFRα) may provide a new therapeutic target for the treatment of rheumatoid arthritis (RA). Therefore, we investigated the cellular expression of GM-CSFRα in RA synovial tissue and investigated the effects of anti-GM-CSFRα antibody treatment in vitro and in vivo in a preclinical model of RA. Methods We compared GM-CSFRα expression on macrophages positive for CD68 or CD163 on synovial biopsy samples from patients with RA or psoriatic arthritis (PsA) to disease controls. In addition, we studied the effects of CAM-3003, an anti-GM-CSFR antibody in a collagen induced arthritis model of RA in DBA/1 mice. The pharmacokinetic profile of CAM-3003 was studied in naïve CD1(ICR) mice (see online supplement) and used to interpret the results of the pharmacodynamic studies in BALB/c mice. Results GM-CSFRα was expressed by CD68 positive and CD163 positive macrophages in the synovium, and there was a significant increase in GM-CSFRα positive cells in patients in patients with RA as well as patients with PsA compared with patients with osteoarthritis and healthy controls. In the collagen induced arthritis model there was a dose dependent reduction of clinical arthritis scores and the number of F4/80 positive macrophages in the inflamed synovium after CAM-3003 treatment. In BALB/c mice CAM-3003 inhibited recombinant GM-CSF mediated margination of peripheral blood monocytes and neutrophils. Conclusions The findings support the ongoing development of therapies aimed at interfering with GM-CSF or its receptor in various forms of arthritis, such as RA and PsA.
Collapse
Affiliation(s)
- D E A Greven
- Department of Clinical Immunology and Rheumatology, Academic Medical Center/ University of Amsterdam, Amsterdam, The Netherlands
| | - E S Cohen
- Department of Respiratory, Inflammation and AutoImmunity Research, MedImmune Limited, Cambridge, UK
| | - D M Gerlag
- Department of Clinical Immunology and Rheumatology, Academic Medical Center/ University of Amsterdam, Amsterdam, The Netherlands GlaxoSmithKline, Cambridge, UK
| | - J Campbell
- Department of Respiratory, Inflammation and AutoImmunity Research, MedImmune Limited, Cambridge, UK
| | - J Woods
- Department of Respiratory, Inflammation and AutoImmunity Research, MedImmune Limited, Cambridge, UK
| | - N Davis
- Department of Respiratory, Inflammation and AutoImmunity Research, MedImmune Limited, Cambridge, UK
| | - A van Nieuwenhuijze
- Inflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
| | - A Lewis
- Department of Respiratory, Inflammation and AutoImmunity Research, MedImmune Limited, Cambridge, UK
| | - S Heasmen
- Department of Respiratory, Inflammation and AutoImmunity Research, MedImmune Limited, Cambridge, UK
| | - M McCourt
- Department of Respiratory, Inflammation and AutoImmunity Research, MedImmune Limited, Cambridge, UK
| | - D Corkill
- Department of Respiratory, Inflammation and AutoImmunity Research, MedImmune Limited, Cambridge, UK
| | - A Dodd
- Department of Respiratory, Inflammation and AutoImmunity Research, MedImmune Limited, Cambridge, UK
| | - J Elvin
- Department of Respiratory, Inflammation and AutoImmunity Research, MedImmune Limited, Cambridge, UK
| | - G Statache
- Department of Clinical Immunology and Rheumatology, Academic Medical Center/ University of Amsterdam, Amsterdam, The Netherlands
| | - I P Wicks
- Inflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
| | - I K Anderson
- Department of Respiratory, Inflammation and AutoImmunity Research, MedImmune Limited, Cambridge, UK
| | - A Nash
- Department of Research and Development, CSL Limited, Parkville, Victoria, Australia
| | - M A Sleeman
- Department of Respiratory, Inflammation and AutoImmunity Research, MedImmune Limited, Cambridge, UK
| | - P P Tak
- Department of Clinical Immunology and Rheumatology, Academic Medical Center/ University of Amsterdam, Amsterdam, The Netherlands GlaxoSmithKline, Stevenage, UK University of Cambridge, Cambridge, UK
| |
Collapse
|
45
|
Tuychiev L, Khudaykulova G, Daminov T, Aladova L, Davis N. Height-weight indices in HIV-infected children. Int J Infect Dis 2014. [DOI: 10.1016/j.ijid.2014.03.691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
46
|
Gattorno M, Obici L, Meini A, Tormey V, Abrams K, Davis N, Andrews C, Lachmann H. THU0396 Efficacy and safety of canakinumab in patients with TNF receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.2361] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
47
|
Islam SU, Henry A, Khan T, Davis N, Zenios M. The outcome of paediatric LCP hip plate use in children with and without neuromuscular disease. Musculoskelet Surg 2013; 98:233-9. [PMID: 24297691 DOI: 10.1007/s12306-013-0308-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2013] [Accepted: 11/23/2013] [Indexed: 11/29/2022]
Abstract
BACKGROUND The relatively new paediatric LCP hip plate (Synthes GmBH Eimattstrasse 3 CH-4436 Oberdorff) is used in children, both with and without neuromuscular disease, for fixation of proximal femoral osteotomy for a variety of indications. MATERIALS AND METHODS We retrospectively reviewed the notes and radiographs of all those children who have had paediatric LCP device for the fixation of proximal femoral osteotomy and proximal femur fractures in our institution (Royal Manchester Children's Hospital), between October 2007 and July 2010, for their clinical progress, mobilization status, radiological healing and any complications. RESULTS Forty-three paediatric LCP hip plates were used in 40 patients (27 males and 13 females) for the fixation of 40 proximal femoral osteotomies and three proximal femur fractures. This included 13 children with underlying neuromuscular pathology and 27 children without neuromuscular disease. All osteotomies and fractures radiologically healed within 6 months [majority (n = 40) within 3 months]. There was no statistically significant difference (p = 0.45) in the neck shaft angle between the immediately post-operative and final X-rays after completion of bone healing. There were no implant-related complications both in patients with and without neuromuscular disease. No metalwork loosening was observed and no plate revisions were required. Three post-operative fractures occurred in patients with neuromuscular pathology treated with post-operative plaster immobilisation. CONCLUSION The paediatric LCP hip plate provides a stable and reliable fixation of the proximal femoral osteotomy performed for a variety of paediatric orthopaedic conditions.
Collapse
Affiliation(s)
- S U Islam
- Royal Manchester Children's Hospital, Manchester, UK
| | | | | | | | | |
Collapse
|
48
|
Gül A, Özdoğan H, Kasapçopur Ö, Erer B, Uğurlu S, Davis N, Sevgi S. PW01-015 – Canakinumab in adults with colchicin resistant FMF. Pediatr Rheumatol Online J 2013. [PMCID: PMC3952949 DOI: 10.1186/1546-0096-11-s1-a68] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
49
|
Lachmann HJ, Obici L, Meini A, Tormey V, Abrams K, Davis N, Andrews C, Bhansali SG, Gattorno M. OR10-006 - Canakinumab in patients with TRAPS. Pediatr Rheumatol Online J 2013. [PMCID: PMC3953131 DOI: 10.1186/1546-0096-11-s1-a189] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
50
|
Kuemmerle-Deschner JB, Tilson H, Hawkins PN, van der Poll T, Walker UA, Rauer B, Nebesky JM, Kim D, Davis N, Hoffman H. THU0464 Safety Results from the B-Confident Registry in Canakinumab-Treated Patients with Cryopyrin-Associated Periodic Syndrome (CAPS). Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|